CpG oligodeoxynucleotide capable of regulating body immunity and application of CpG oligodeoxynucleotide
By optimizing the sequence and structure of A-type CpG oligodeoxynucleotides, the problems of drug properties and aggregate stability are solved, and higher immune activity and drug properties are achieved, which are suitable for the treatment of various diseases.
Patent Information
- Application Number
- CN202410974580.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-07-21
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-19
AI Technical Summary
Traditional A-type CpG oligomeric deoxynucleotides are not prone to aggregation, resulting in insufficient drug properties and are not successfully developed as clinical drugs. Moreover, the aggregate size and stability of their self-aggregation model are difficult to control, affecting immune activity and safety.
A new CpG oligodeoxynucleotide sequence was designed to optimize its primary and secondary structures by nucleotide replacement and modification of the core sequence, forming more stable aggregates, and improving its drug properties and immune activity. , the specific sequence is 5'-(G)n-core sequence-(N)q-(G)m-3', where the value range of n, m, q is optimized to ensure the controllability and stability of the aggregates .
It has achieved higher immune activity and drug properties, especially the AM1012-05 sequence is more stable at high temperature, and the aggregate controllability is better than traditional A-type CpG, with better production stability, anti-tumor and anti-allergic rhinitis , treatment potential of asthma and other diseases.
Smart Images

Figure CN118909014A_ABST
Abstract
Description
[0001] The present invention claims priority to a prior application filed with the State Intellectual Property Office of China on July 21, 2023, with patent application number 202310902755.X and invention title “CpG oligodeoxynucleotides with the ability to regulate immunity and their applications”. The entire text of the above-mentioned prior application is incorporated into the present invention by reference. Technical Field
[0002] The invention belongs to the field of oligodeoxynucleotides, and in particular relates to a CpG oligodeoxynucleotide capable of regulating body immunity and an application thereof. Background Art
[0003] TLR9 is an innate immune receptor in mammals, present in endosomes, and its ligand is an unmethylated CpG-containing oligodeoxyribonucleotide (ODN). Depending on the type and structure, after CpG-ODN enters the endosome, it can bind to TLR9 and activate the IRF-7 or NF-κB signaling pathway, producing inflammatory factors such as type I interferon or IL-6 to intervene in the immune response.
[0004] According to the difference in structural characteristics and immune effects, CpG ODN can be divided into three types: A, B, and C. Type A CPG enters the early endosomes of plasmacytoid dendritic cells (pDCs) and binds to the TLR9 receptor inside, activating the IRF-7 signaling pathway and inducing the production of a large number of type I interferons (IFN-α / IFN-β) and type III interferons (IFN-λ). Type I interferons, as a general immune regulatory cytokine, act on downstream immune cells, including but not limited to NK cells, CD8 + T cells, CD4 +T cells, γ / δT cells, macrophages, etc., induce the production of cytokines such as type II interferon (IFN-γ). Type B CpG is a fully sulfo-modified linear CpG ODN, and its main target cells are B lymphocytes. Type B CpG enters the late endosome and binds to TLR9, activates NF-κB, and produces a series of immune responses, including the secretion of inflammatory cytokines such as IL-6, IL-1 and TNF-, and promotes B cell proliferation. Type B CpG can be used as a vaccine adjuvant to significantly improve the level of antibodies. Type C CpG is a fully sulfo-modified CpG ODN, which contains part of the structure of type A CPG and part of the structure of type B CPG. It has both a palindromic sequence that can form a dimer and a non-palindromic linear structure. Type C CpG can enter the early endosome and bind to TLR9, and can also enter the late endosome and bind to TLR9. Therefore, it has the activity of both type A and type B CpG-ODN, which can not only activate the IRF-7 signaling pathway, but also activate the NF-kB pathway to produce type I interferon and inflammatory cytokines. Although type C CpG has the characteristics of both type A and type B CpG, its ability to induce interferon and inflammatory molecules is significantly lower than the activity of type A or type B CpG respectively.
[0005] Preclinical animal experiments of type B CPG have shown that it can successfully treat allergic rhinitis, asthma, various microbial infections, and anti-tumor. In the past 20 years, there have been more than 100 papers reporting on the preclinical treatment of various diseases with CPG. The representative of type B CPG, CPG-1018, has been successfully approved for marketing as a hepatitis B vaccine adjuvant in 2017.
[0006] Current studies have shown that when administered through different routes, type A CpG ODN can induce strong innate immunity (type I / II / III interferons) and Th1 immune responses (DC, NK and CD8 +It can activate T cells, produce IL-12), and regulate immune function, thereby inhibiting Th2 and Th17 immune responses. Through these immune responses, it can treat diseases caused by allergic inflammation and non-allergic inflammation, resist infection by pathogenic microorganisms, directly or indirectly kill tumor cells, reduce the formation of Aβ plaques, and improve the immunogenicity of vaccines. This also lays the foundation for its application in infectious diseases, cancer, immune adjuvants, allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil-related diseases, Alzheimer's disease, wound healing, wound infection prevention and treatment, etc. (Montamat et al., Fronteers in Immunol. 2021. doi: 10.3389 / fimmu.2021.590054; Scheiermann et al., Vaccine 2014. 32: 6377-6389; Shirota and Klinman., Immunopotentiators in Modern Vaccines ISBN 978-0-12-804019-5, http: / / dx.doi.org / 10.1016 / B978-0-12-804019-5.00009-8; Beeh et al., J Allergy Clin Immunol 2013;131:866-74;Hanagata N.etal.,Int J Nanomedicine.2012;7:2181-95;Kayraklioglu et al.,.Methods MolBiol.2021;2197:51-85;Fan et al.,Clin Cancer Res.2012Oct15;18(20):5628-38; Senti et al., Clin Exp Allergy.2009Apr;39(4):562-70; Scholtzova et al., ActaNeuropathol Commun.2014Sep 2;2:101; Wanke-Jellinek et al.,J Immunol.2016Jan15;196(2):767-77).
[0007] Due to the easy aggregation of type A CPG, its drugability is very poor. Even more than 20 years after the discovery of type A CPG, there have been very few clinical trials and no drugs have been approved for marketing. Historically, three organizations have tried to improve the drugability of type A CPG through various methods: 1. Cytos Biotechnology AG used virus-like particles (VLPs) to encapsulate type A CPG (QbG-10). Although the drugability was improved, the VLP encapsulation made type A-CPG no longer a simple CPG, but a CPG with strong adjuvant function (Storni et al., J. Immunol. 2004.172:1777-1785); 2. FDA scientists added fma (a small molecule compound) to the 5 Gs at the 3' end of type A CPG, turning it into a temperature-sensitive prodrug. After entering the cell, fma automatically fell off at 37°C, causing type A CPG to re-aggregate and exert its drug efficacy. However, such modification cannot completely prevent aggregation in vitro, and the modification of fma limits the safety and tolerability of the drug (Puig et al., Puig, Nucleic acids Research.2005.34:6488-6495); 3. Japanese scientists reported in 2015 that the drugability of type A CpG can be greatly improved by adding 40 adenine deoxyribonucleotides (poly-A) to the 3' end of type A CpG. However, the addition of 40 adenines greatly increases the production cost, and because it is fully thiolated, it can increase the production of IL-6 inflammatory molecules, which limits its safety and tolerance (Aoshi et al., J. Immunol. Research.2015.http: / / dx.doi.org / 10.1155 / 2015 / 316364). Therefore, there has been no successful case of traditional type A CpG being developed into a drug, and no clinical trials have been reported.
[0008] The principle of traditional A-type CPG design is to achieve the production of polymers through the complete palindrome of the core sequence of 8-12 nucleotides (including 1 or more CpGs) and the poly-G at both ends. The polymer can present the core sequence of CpG to TLR9 on the early endosome instead of TLR9 on the late endosome, so that it activates the IRF-7 signaling pathway and produces type I interferon. The formation of polymers is necessary to activate the IRF-7 signaling pathway (Kerkmann et al., J. Bio. Chem., 2005. 280: 8086-8093; Wu et al., J. Bio. Chem., 2004. 279: 33071-33078). However, monomeric CPG ODN cannot activate the IRF-7 signaling pathway. For example, B-type CPG is a monomer in solution and can only bind to TLR9 in the late endosome, thereby activating the NF-kB signaling pathway and inducing the production of inflammatory factors instead of type I interferon. Since type A CPG must form aggregates to be active, the generation of aggregates often easily forms uncontrollable large aggregates, which greatly reduces the drugability. This is the main reason why there has been no successful clinical research and development case since the invention of type A CPG. Therefore, how to ensure that type A CPG has aggregation and controllable aggregation at the same time has become the key to whether this type of molecule can be developed into a clinically effective drug.
[0009] The traditional self-aggregation model of type A CPG was proposed by Kerkmann et al. in 2005 (Kerkmann et al., J. Bio. Chem., 2005. 280: 8086-8093): two palindromic complementary monomers form dimers through Watson-Crick connection, and the poly-G at both ends of the dimer form Hoogsteen base pairing through hydrogen bonds of guanylate to form a tetramer (G-tetrad). Then the dimers and tetramers continue to aggregate through G-tetrad, and in this way, a larger aggregate is formed. Another model is based on the secondary structure of type A CPG. Type A CPG monomers can form palindromic structures within the monomers, and the poly-G at both ends can form higher aggregates through Hoogsteen pairing. Therefore, it can be learned from these models that the size and stability of the aggregate depends on the number of surrounding Hoogsteen connections and its unique spatial structure. Our early research found that from the perspective of secondary structure, the completely palindromic form before and after poly-G can reduce the energy required for aggregation and make aggregation easier to form. Therefore, by establishing a certain spatial barrier between polyG and palindrome, the energy of forming G-tetrad may be increased, making the polymer relatively difficult to form or relatively loose after formation. At the same time, combined with the selection of the number of poly G at both ends, the polymer may be stabilized within a certain size range. Based on the above considerations, the present invention designs multiple core sequences, and while the core series remains unchanged, a deoxyribonucleotide replacement experiment is performed on the two ends of type A CPG, and the formation rules of type A CPG polymers are found, and the relationship between it and the stimulation of type I interferon production is discovered. Summary of the invention
[0010] The technical solution of the present invention is as follows:
[0011] A CpG oligodeoxynucleotide with the ability to regulate the body's immunity. The CpG oligodeoxynucleotide with the ability to regulate the body's immunity of the present invention has a sequence structure of 5'-(G) n -Core Sequence-(N) q -(G) m- 3', the core sequence is a palindromic sequence, the N is any one of the three bases of adenine deoxyribonucleotide (A), thymine deoxyribonucleotide (T), and cytosine deoxyribonucleotide (C); the G is guanine deoxyribonucleotide; the q, n, and m are all integers; the n value range is 2 to 11, the q value range is 0 to 10, and the m value range is 2 to 11.
[0012] Preferably, the value range of n is 3-4, and the value range of q is 1-5.
[0013] Preferably, the core sequence is at least one of CGCGACGCGTCGCG, ACGATCGAGATCGT, AGGATCG ATCCT, TTCGATCGATCGAA, CGATCGATCG, GACGATCGTC, and TGCATCGATGCA; when the core sequence is CGCGACGCGTCGCG, the value range of q is 0 to 10, the value range of n is 0 to 3, and the value range of m is 2 to 11;
[0014] Or, when the core sequence is ACGATCGAGATCGT, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11;
[0015] Or, when the core sequence is AGGATCGATCCT, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11;
[0016] Or, when the core sequence is TTCGATCGATCGAA, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11;
[0017] Or, when the core sequence is CGATCGATCG, the value range of q is 0 to 10, the value range of n is 1 to 11, and the value range of m is 2 to 11;
[0018] Or, when the core sequence is GACGATCGTC, q is 0, n is in the range of 0 to 3, and m is in the range of 2 to 11; or q is in the range of 1 to 10, n is in the range of 2 to 11, and m is in the range of 2 to 11;
[0019] Or, when the core sequence is TGCATCGATGCA, q is 0, n is 1, 3, 4 or 5, and m is in the range of 2 to 11; or q is in the range of 1 to 10, n is in the range of 2 to 11, and m is in the range of 2 to 11.
[0020] Preferably, the above-mentioned CpG oligodeoxynucleotide comprises at least one of the deoxynucleotide sequences shown in SEQ ID NO.1 to SEQ ID NO.82.
[0021] Preferably, the CpG oligodeoxynucleotide itself may contain at least one of thio modification, fluoro modification, methoxy modification, locked nucleic acid modification, and nanoparticle modification.
[0022] Preferably, the thiolation modification site is on the polyguanylate at the 5' end and / or the 3' end.
[0023] Preferably, the nanoparticles used in the nanoparticle modification include at least one of PLGA, chitosan, lipid nanoparticles, and liposomes.
[0024] A CpG oligodeoxynucleotide preparation comprises the above-mentioned CpG oligodeoxynucleotide and excipients, wherein the excipients comprise at least one of pH buffer pair, glycine, trehalose, mannitol, sucrose, arginine, lysine, histidine, glycerol, propylene glycol, Pluronic F127, Pluronic F68, Tween 20, Tween 80, benzalkonium chloride, disodium edetate, sodium citrate, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methyl beta-cyclodextrin and polyethylene glycol.
[0025] Preferably, the metal ions of the CpG oligodeoxynucleotide preparation include sodium, potassium, magnesium, calcium, zinc, and iron, with a total concentration ranging from 0.1 to 90 mM.
[0026] Preferably, the pH value of the CpG oligodeoxynucleotide preparation is between 7-9.
[0027] An application of the CpG oligodeoxynucleotide in the preparation of a drug for regulating respiratory immune response.
[0028] A use of the above CpG oligodeoxynucleotide in the preparation of a drug for preventing and treating respiratory diseases, wherein the respiratory diseases include at least one of respiratory viral infections, respiratory bacterial infections, respiratory fungal infections, respiratory parasitic infections, and respiratory allergic diseases. The respiratory virus in the respiratory viral infection includes at least one of COVID-19 virus, influenza virus, RSV virus, and SARS-Cov.
[0029] A use of the above CpG oligodeoxynucleotide in the preparation of a drug for preventing and treating a non-respiratory tract infection disease, wherein the non-respiratory tract infection disease comprises at least one of HIV virus infection, HBV virus infection, and HCV virus infection.
[0030] A use of the CpG oligodeoxynucleotide in the preparation of a drug for regulating the proliferation function of immune cells or a drug for regulating the release of cytokines from immune cells.
[0031] A use of the above CpG oligodeoxynucleotide in the preparation of immune adjuvants.
[0032] A use of the CpG oligodeoxynucleotide in preparing medicines for preventing and treating viral infections.
[0033] An application of the CpG oligodeoxynucleotide in the preparation of a drug for treating tumors, wherein the CpG oligodeoxynucleotide is the only anti-tumor drug component.
[0034] An anti-tumor composition comprises the above-mentioned CpG oligodeoxynucleotide and an anti-tumor drug, wherein the anti-tumor drug includes but is not limited to a PD-1 anti-tumor drug, a PDL-1 anti-tumor drug and an anti-tumor cell therapy, and the CpG oligodeoxynucleotide in the composition serves as a component with anti-tumor efficacy or an immune adjuvant.
[0035] A use of the above CpG oligodeoxynucleotide in preparing vaccines for human or animal use.
[0036] A use of the above CpG oligodeoxynucleotide in treating central nervous system diseases, wherein the central nervous system diseases include but are not limited to Alzheimer's disease.
[0037] An application of the CpG oligodeoxynucleotide in the preparation of a drug for preventing and treating secondary infection after trauma.
[0038] An application of the CpG oligodeoxynucleotide in preparing a medicine for promoting wound healing.
[0039] A use of the above CpG oligodeoxynucleotide in the preparation of a drug for treating allergic rhinitis and / or atopic dermatitis and / or asthma and / or chronic obstructive pulmonary disease and / or eosinophil-related diseases.
[0040] A medicine prepared by using the above CpG oligodeoxynucleotide, the dosage form of the medicine is injection, tablet, lyophilized agent, inhaler, nasal drops, nasal spray, rectal suppository, eye drops, smear, lotion, gel.
[0041] A CpG oligodeoxynucleotide external preparation as described above: comprising the CpG oligodeoxynucleotide as described in any one of claims 1 to 5 and excipients, wherein the excipients include glyceryl behenate, liquid paraffin, vaseline, medium chain triglycerides, cocoyl caprylate, glyceryl mono- and distearate, hydroxypropyl methylcellulose, carbomer, xanthan gum, sodium carboxymethyl cellulose, poloxamer 407, polyethylene glycol cetearyl alcohol ether, poloxamer 188, oleoyl polyoxyethylene glyceride, polyethylene glycol-7 stearate, caprylic capric macrogol glyceride, sodium lauryl sulfate, propylene glycol monofatty acid ester, polyglyceryl oleate, propylene glycol laurate, propylene glycol, isopropyl myristate, and polyglyceryl oleate.
[0042] The above-mentioned CpG oligodeoxynucleotide adjuvant and a preparation in combination with other types of adjuvants are used for vaccines for human or animals: comprising CpG oligodeoxynucleotide itself or in combination with other types of adjuvants, wherein the other types of adjuvants are preferably aluminum hydroxide and aluminum phosphate.
[0043] Beneficial effects achieved by the present invention:
[0044] Different from the traditional A-type CpG complete palindrome design, the present invention provides a CpGODN sequence with a completely new structure and sequence. These sequences replace the nucleotides at both ends of ODN to find out the relationship and related rules between its drugability and activity. Compared with the published sequences, it has a unique primary structure and secondary structure, overcomes the problem of traditional A-type CpG easy aggregation and poor drugability, has higher immune activity and drugability, especially the AM1012-05 sequence, the secondary structure formed by it is more stable at high temperature than similar products, and its aggregate controllability is better than other sequences of the same type. In the production process, the stability between batches is better and has better drugability. At the same time, AM1012-05 can effectively penetrate the human respiratory epithelial mucosa (RPMI 2650 cells) permeable membrane, and also shows excellent immune activation activity in animals, with excellent blocking of respiratory virus infection and transmission, and has the potential to play anti-tumor, treat allergic rhinitis, asthma, chronic obstructive pulmonary disease, eosinophil-related diseases, atopic dermatitis, Alzheimer's disease, and be used in the prevention and treatment of secondary infections after trauma and promote wound healing drugs by activating and regulating the immune system. At the same time, it has the potential to be an independent vaccine adjuvant or adjuvant system component. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] In order to more clearly illustrate the technical solution of the present application, the drawings required for use in the embodiments are briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0046] Figure 1 To evaluate the IFN-γ stimulating ability of different CpG sequences on NK-92 cells; Figures A, B, C, D, and E tested the IFN-γ stimulating ability of different CpG sequences on NK-92 cells under the same experimental system;
[0047] Figure 2 Comparison of the stimulating ability of different CpG sequences on SD rat spleen cells; Figure A shows that different CpG sequences stimulate rat spleen cells to secrete IFN-γ, Figure B shows that different CpG sequences stimulate rat spleen cells to secrete TNF-α, and Figure C shows that different CpG sequences stimulate rat spleen cells to secrete IL-6;
[0048] Figure 3 To evaluate the IFN-γ stimulating ability of AM1012-05 on NK-92 cells;
[0049] Figure 4 The stimulating ability of AM1012-05 on BALB / c mouse spleen cells was evaluated; wherein, Figure A shows that AM1012-05 stimulated BALB / c mouse spleen cells to secrete IL-6, Figure B shows that AM1012-05 stimulated BALB / c mouse spleen cells to secrete IFN-γ, Figure C shows that AM1012-05 stimulated BALB / c mouse spleen cells to secrete TNF-α, and Figure D shows that AM1012-05 stimulated BALB / c mouse spleen cells to secrete IFN-α;
[0050] Figure 5 The stimulating ability of AM1012-05 on C57BL6 mouse spleen cells was evaluated; wherein, Figure A shows that AM1012-05 stimulated C57BL6 mouse spleen cells to secrete IL-6, Figure B shows that AM1012-05 stimulated C57BL6 mouse spleen cells to secrete IFN-γ, Figure C shows that AM1012-05 stimulated C57BL6 mouse spleen cells to secrete TNF-α, and Figure D shows that AM1012-05 stimulated C57BL6 mouse spleen cells to secrete IFN-α;
[0051] Figure 6 The stimulating ability of AM1012-05 on cotton rat spleen cells is evaluated; Figure A shows that AM1012-05 increases the mRNA level of IFN-α in cotton rat spleen cells, Figure B shows that AM1012-05 increases the mRNA level of IFN-γ in cotton rat spleen cells, Figure C shows that AM1012-05 increases the mRNA level of TNF-α in cotton rat spleen cells, and Figure D shows that AM1012-05 increases the mRNA level of CXCL-10 in cotton rat spleen cells;
[0052] Figure 7 The stimulating ability of AM1012-05 on rat spleen cells (mRNA level) is evaluated; wherein, Figure A shows that AM1012-05 increases the mRNA level of IFN-α in rat spleen cells, and Figure B shows that AM1012-05 increases the mRNA level of CXCL-10 in rat spleen cells;
[0053] Figure 8 Evaluation of the stimulating ability of AM1012-05 on rat spleen cells (protein level); wherein, Figure A shows that AM1012-05 stimulates rat spleen cells to secrete IFN-γ, Figure B shows that AM1012-05 stimulates rat spleen cells to secrete IL-6, and Figure C shows that AM1012-05 stimulates rat spleen cells to secrete TNF-α;
[0054] Fig. 9The stimulating ability of AM1012-05 on beagle dog PBMC is evaluated; wherein, Figure A shows that AM1012-05 increases the mRNA level of IFN-α in beagle dog PBMC, Figure B shows that AM1012-05 increases the mRNA level of IFN-γ in beagle dog PBMC, Figure C shows that AM1012-05 increases the mRNA level of IFN-λ in beagle dog PBMC, Figure D shows that AM1012-05 increases the mRNA level of IL-6 in beagle dog PBMC, Figure E shows that AM1012-05 increases the mRNA level of CXCL-10 in beagle dog PBMC, and Figure F shows that AM1012-05 increases the mRNA level of TNF-α in beagle dog PBMC;
[0055] Fig.10 It is an evaluation of the stimulating ability of CpG ODN on human PBMC; wherein, Figure A shows that AM1012-05 stimulates human PBMC to secrete IFN-α, Figure B shows that AM1012-05 stimulates human PBMC to secrete IFN-γ, Figure C shows that AM1012-05 stimulates human PBMC to secrete IFN-λ, Figure D shows that AM1012-05 stimulates human PBMC to secrete TNF-α, Figure E shows that AM1012-05 stimulates human PBMC to secrete IL-6, Figure F shows that AM1012-05 stimulates human PBMC to secrete CXCL-10, and Figure G shows that AM1012-05, CpG 2216, and CpG D19 stimulate human PBMC to secrete IFN-α;
[0056] Fig.11 This is the result of serum stability electrophoresis test of CpG ODN;
[0057] Fig.12 Aggregation state distribution of different CpG ODN aggregates; the left picture is the electrophoresis detection of type A CpG aggregation state distribution (2 hours), and the right picture is the electrophoresis detection of type A CpG aggregation state distribution (24 hours);
[0058] Fig.13 Aggregation analysis of AM1012-05 and CpG 2216 solutions in static and vortexed states;
[0059] Fig.14 Comparison of secondary structures of different sequence samples at -20°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0060] Fig.15 Comparison of secondary structures of different sequence samples at 0°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0061] Fig.16 Comparison of secondary structures of different sequence samples at 4°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0062] Fig.17 Comparison of secondary structures of different sequence samples at 25°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0063] Fig.18 Comparison of secondary structures of different sequence samples at 37°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0064] Fig.19 Comparison of secondary structures of different sequence samples at 40°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0065] Fig. 20 Comparison of secondary structures of different sequence samples at 50°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0066] Fig.21 Comparison of secondary structures of different sequence samples at 60°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0067] Fig. 22 Comparison of secondary structures of different sequence samples at 70°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0068] Fig.23 Comparison of secondary structures of different sequence samples at 80°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0069] Fig.24 Comparison of secondary structures of different sequence samples at 90°C; Figure A is CpG 2216, Figure B is E41, Figure C is AM1012-03, and Figure D is AM1012-05;
[0070] Fig.25The effect of CpG ODN treated at different temperatures on IFN-γ secretion of rat splenocytes;
[0071] Fig.26 The particle size analysis diagram of PLGA nanoformulation of CpG ODN;
[0072] Fig. 27 The particle size analysis diagram of the prepared chitosan nanoformulation of CpG ODN;
[0073] Fig.28 It is a particle size analysis diagram of the lipid nanoparticle preparation of CpG ODN;
[0074] Fig.29 Particle size analysis of PLGA nanoparticles as an immune adjuvant for the preparation of CpG ODN;
[0075] Fig.30 This is a graph evaluating the effect of the formulation components on the IFN-γ stimulating ability of AM1012-05 on NK-92 cells;
[0076] Fig.31 The effects of AM1012-05 on the relative expression of immune-related mRNA in mouse lung and spleen tissues; wherein, Figure A shows that AM1012-05 increases the mRNA level of IFN-α in mouse lung tissues, Figure B shows that AM1012-05 increases the mRNA level of IFN-γ in mouse lung tissues, Figure C shows that AM1012-05 increases the mRNA level of CXCL-10 in mouse lung tissues, Figure D shows that AM1012-05 increases the mRNA level of IFN-α in mouse spleen tissues, Figure E shows that AM1012-05 increases the mRNA level of IFN-γ in mouse spleen tissues, and Figure F shows that AM1012-05 increases the mRNA level of CXCL-10 in mouse spleen tissues;
[0077] Fig.32 The relative expression of CXCL-10 mRNA in the lungs of mice after intranasal administration of AM1012-05;
[0078] Fig.33 AM1012-05 induced mouse lung tissue to secrete cytokines at different dosing frequencies; Figure A shows AM1012-05 induced mouse lung tissue to secrete CXCL-10 at different dosing frequencies, and Figure B shows AM1012-05 induced mouse lung tissue to secrete IFN-γ at different dosing frequencies;
[0079] Fig.34 AM1012-05 activated human PBMC to kill N87 cells;
[0080] Fig.35AM1012-05 activated human PBMC to kill MDA-MB-231 cells;
[0081] Fig.36 The evaluation of the ability of AM1012-05 to relieve allergic rhinitis in mice; Figure A shows that AM1012-05 reduces the number of sneezes in mice with allergic rhinitis, Figure B shows that AM1012-05 reduces the number of nose scratching in mice with allergic rhinitis, Figure C shows that AM1012-05 reduces the runny nose in mice with allergic rhinitis, Figure D shows that AM1012-05 reduces the number of eosinophils in the nasal mucosa of mice with allergic rhinitis, Figure E shows that AM1012-05 reduces the expression of IL-4 in the serum of mice with allergic rhinitis, and Figure F shows that AM1012-05 increases the expression of IFN-γ in the serum of mice with allergic rhinitis;
[0082] Fig.37 Results of immune cell analysis of nasal lavage fluid from mice with allergic rhinitis treated with AM1012-05;
[0083] Fig.38 Evaluation of the in vitro anti-RSV activity of AM1012-05; Figure A shows the PBMC co-incubation supernatant of AM1012-05 preventing the proliferation of RSV in cells, and Figure B shows the elimination of RSV in host cells by AM1012-05;
[0084] Fig.39 To evaluate the anti-atopic dermatitis activity of AM1012-05 (IgE level);
[0085] Fig.40 Evaluation of the adjuvant application of AM1012-05: Figure A shows the IgG immune titer test results 7 days after the first immunization; Figure B shows the IgG immune titer test results 7 days after the second immunization; Figure C shows the IgG immune titer test results 7 days after the third immunization; Figure D shows the IgG immune titer test results 21 days after the third immunization; Figure E shows the IgG immune titer test results 35 days after the third immunization;
[0086] Fig.41 Evaluation of the adjuvant application of AM1012-05: Figure A shows the IgG1 immune titer test results 7 days after the first immunization; Figure B shows the IgG1 immune titer test results 7 days after the second immunization; Figure C shows the IgG1 immune titer test results 7 days after the third immunization; Figure D shows the IgG1 immune titer test results 21 days after the third immunization; Figure E shows the IgG1 immune titer test results 35 days after the third immunization;
[0087] Fig.42Evaluation of the adjuvant application of AM1012-05: Figure A shows the immune titer test results of IgG2a 7 days after the first immunization; Figure B shows the immune titer test results of IgG2a 7 days after the second immunization; Figure C shows the immune titer test results of IgG2a 7 days after the third immunization; Figure D shows the immune titer test results of IgG2a 21 days after the third immunization; Figure E shows the immune titer test results of IgG2a 35 days after the third immunization. DETAILED DESCRIPTION
[0088] The specific implementation methods of the present application are described in detail below. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present application.
[0089] Example 1: Design and synthesis of CpG ODN molecules
[0090] The present invention designs a plurality of CpG ODN sequences (see Table 1), and uses solid phase synthesis for chemical synthesis, and then undergoes aminolysis, purification, desalting and concentration, packaging and freeze-drying to obtain the final product. The specific operation is as follows:
[0091] (1) Solid phase synthesis: Solid phase synthesis is carried out under computer control and consists of four repeated synthesis steps (detritylation, coupling, sulfidation, capping) and the last step of dephosphorylation of the protective group of the skeleton;
[0092] (2) Aminolysis: After synthesis, the oligonucleotide is cut off from the support using ammonia or an organic amine. The oligonucleotide is dissolved in the solution, and the universal linker group connected to the first base at the 3' end and the protecting group of the amino group on the base are removed;
[0093] (3) Purification: The crude product obtained by aminolysis is purified and separated by ion exchange chromatography, reverse phase chromatography or electrophoresis to obtain a purified product;
[0094] (4) Desalting and concentrating: using ultrafiltration equipment to desalt and concentrate the purified product;
[0095] (5) Packaging and freeze-drying: A white, off-white or light yellow loose body is obtained by freeze-drying.
[0096] Types of nucleic acid modifications include, but are not limited to, thiolation modifications.
[0097] Table 1 Sequences involved in the present invention
[0098]
[0099]
[0100]
[0101] (Note: * indicates thio modification).
[0102] Example 2: Aggregation and activity analysis of different CpG ODNs
[0103] (I) Analysis of aggregation of different CpG ODNs:
[0104] The aggregation of the freeze-dried powder of some CpG ODN sequences obtained in Example 1 was analyzed by high performance liquid chromatography.
[0105] (II) Detection of the effects of different CpG ODN on IFN-α secretion based on healthy human PBMC cells:
[0106] (1) Take a certain amount of 100 μM CpG ODN solution and prepare it into a certain concentration of stock solution with RPMI 1640 complete medium, then dilute the CpG ODN sample solution with complete medium at a ratio of 4 times to prepare test samples of different concentrations;
[0107] (2) Obtain an appropriate amount of cryopreserved healthy human PBMC cells;
[0108] (3) According to 2×10 5 Cells / well were plated in 96-well plates, and samples of different concentrations were added to each well, and a PBS blank control well was set up;
[0109] (4) Place in a 37°C, 5% CO2 incubator for 16 h;
[0110] (5) Centrifugation to collect the supernatant;
[0111] (6) Detect IFN-α according to the ELISA assay instructions for IFN-α.
[0112] By analyzing the aggregation results (Tables 2-5), it can be found that: (1) By changing the number of G in sequences such as AM1012-05, CpG 2216, and CpG D19, when the number of G at the 5' end is 3-4, the optimal aggregation of the corresponding sequence can be obtained, that is, the content of the aggregate is the smallest; (2) Inserting 1-5 A between the core palindromic sequence of AM1012-05 and the poly-G at the 3' end can further reduce the aggregation content; (3) Inserting 1-10 T or C between the core palindromic sequence of the AM1012-05 sequence and the G at the 3' end can further reduce or increase the aggregation content to varying degrees; (4) Inserting 1-10 A, T, or C between the core palindromic sequence of sequences such as CpG 2216 and CpG D19 and the G at the 3' end can further reduce or increase the aggregation content to varying degrees.
[0113] The target cells of type A CpG are pDC, accounting for about 0.2-0.4% of PBMC cells. The IFN-α produced is mainly derived from pDC. The activity evaluation test results of this embodiment are shown in Tables 2-5. From Table 2, it can be seen that with "CGATCGATCG" as the core sequence of the palindromic structure of type A CpG, different numbers of G are gradually added before the C at its 5' end. As the number of Gs added increases, its stimulating activity on human PBMC gradually increases, and the strongest activity is reached when the number of Gs added is 3 or 4, and then weakens as the number of Gs continues to increase. When the palindromic sequence "TGCATCGATGCA" of CpG D19 is used as the core sequence, different numbers of Gs are gradually added before the T at its 5' end. As the number of Gs added increases, its stimulating activity on human PBMC gradually increases, and the strongest activity is reached when the number of Gs added is 2 to 4, and then weakens as the number of Gs continues to increase. When the palindromic sequence "GACGATCGTC" of CpG 2216 was used as the core sequence, different numbers of G were gradually added before the G at its 5' end. As the number of G added increased, its stimulating activity on human PBMC gradually increased, reaching the strongest activity when the number of G added was 3, and then weakened as the number of G continued to increase.
[0114] The aggregation and activity data of the study on the insertion of A between the 3' end of the palindromic structure of type A CpG and the 5' end of poly-G are summarized in Table 3. It can be seen that "CGATCGATCG" is the core sequence of the palindromic structure of type A CpG, and A is gradually added thereafter (before the 5' end of the poly-G sequence). As the number of inserted A increases, its stimulating activity on human PBMC gradually increases, reaching the strongest when the number of inserted A is 2 to 4, and then weakening as the number of A continues to increase. "TGCATCGATGCA" of CpG D19 is the core sequence of the palindromic structure of type A CpG, and A is gradually added thereafter (before the 5' end of the poly-G sequence). As the number of inserted A increases, its stimulating activity on human PBMC gradually increases, reaching the strongest when the number of inserted A is 2, and then weakening as the number of A continues to increase. When "GACGATCGTC" of CpG 2216 is used as the palindromic core sequence of type A CpG, A is gradually added thereafter (before the 5' end of the poly-G sequence), and its stimulating activity on human PBMC gradually increases with the increase in the number of inserted A, reaching the strongest when the number of inserted A is 2, and then weakens as the number of A continues to increase.
[0115] The aggregation and activity data of the study on the insertion of T between the 3' end of the palindromic structure of type A CpG and the 5' end of poly-G are summarized in Table 4. When the A added to the 3' end of the palindrome sequence "CGATCGATCG" was replaced by T, the addition of 2 Ts or 10 Ts to the end of the palindrome structure kept the A-type CpG activity better; when the A added to the 3' end of the palindrome sequence "TGCATCGATGCA" of CpG D19 was replaced by T, the addition of 2 Ts, 5 Ts or 10 Ts to the end of the palindrome structure kept the A-type CpG activity better, especially D19-11, which added 2 Ts on the basis of D19 and had better activity than D19; when the A added to the 3' end of the palindrome sequence "GACGATCGTC" of CpG 2216 was replaced by T, the addition of 2 Ts, 5 Ts or 10 Ts to the end of the palindrome structure kept the activity better, especially CpG 2216-11, which added 2 Ts on the basis of CpG2216 and had better activity than CpG 2216.
[0116] The aggregation and activity data of the study on the insertion of C between the 3' end of the palindrome structure of A-type CpG and the 5' end of poly-G are summarized in Table 5. When the A added to the 3' end of the palindrome sequence "CGATCGATCG" was replaced with C, the activity of the sequence gradually decreased with the increase of C at the end of the palindrome structure; when the A added to the 3' end of the CpG D19 palindrome sequence "TGCATCGATGCA" was replaced with C, the activity of the sequence gradually decreased with the increase of C at the end of the palindrome structure, but D19-14 added 2 Cs on the basis of D19, and the activity was better than D19; when the A added to the 3' end of the CpG2216 palindrome sequence "GACGATCGTC" was replaced with C, the activity of the sequence gradually decreased with the increase of C at the end of the palindrome structure.
[0117] The present invention breaks through the traditional A-type CpG design concept, creatively establishes a certain spatial barrier between poly-G and palindrome, increases the energy for forming G-tetrad, makes the polymer relatively difficult to form or relatively loose after formation, successfully reduces the generation of A-type CpG aggregates in the solvent, and improves the activity of the designed new A-type CpG. At the same time, in the exploration of the poly-G at the 5' end of the traditional A-type CpG, it was found that when the number of G at the 5' end was 3 to 4, the corresponding sequence had the least aggregates and the best activity, and this rule was verified on multiple CpG palindrome sequences. Based on these rules we found, among the newly designed sequences in this study, AM1012-05 is the best, with 4 G at the 5' end and two A's inserted at the 3' end of the palindrome sequence. It has the characteristics of low aggregation and high activity at the same time, and has very high drugability.
[0118] This study breaks with traditional thinking. By limiting the number of Gs at the 5' end of the palindromic sequence of type A CpG (3 to 4), an appropriate number of A and T (preferably 2) were inserted between the palindromic sequence and the poly-G at the 3' end, which changed the aggregation of type A CpG and improved the activity of type A CpG.
[0119] Table 2 Relationship between the number of 5' end G of type A CpG palindromic sequence and aggregation and activity:
[0120] serial number The number of G Aggregate (%) Activity (IFN-α, pg / mL) AM1012-05-18 1 16.01 <![CDATA[287.8±149.5 a ]]> AM1012-05-17 2 7.12 <![CDATA[188.6±69.5 a ]]> AM1012-05-16 3 3.03 <![CDATA[615.3±58.3 a ]]> AM1012-05 4 0.7 <![CDATA[573.6±47.2 a ]]> AM1012-05-15 5 10.63 <![CDATA[337.8±109.7 a ]]> AM1012-05-14 6 26.38 <![CDATA[107.8±75.8 a ]]> D19-01 1 17.11 <![CDATA[276.3±96.6 b ]]> D19 2 4.94 <![CDATA[531.1±137.6 b ]]> D19-02 3 0.61 <![CDATA[481.1±48.1 b ]]> D19-03 4 0.68 <![CDATA[527.1±106.7 b ]]> D19-04 5 6.05 <![CDATA[203.4±45.6 b ]]> 2216-04 1 23.28 <![CDATA[256.8±155.4 b ]]> 2216-03 2 16.52 <![CDATA[349.1±122.4 b ]]> 2216-02 3 2,17 <![CDATA[323.5±145.2 b ]]> 2216-01 4 0.83 <![CDATA[548.5±40.4 b ]]> 2216 5 4.21 <![CDATA[310.2±74.1 b ]]>
[0121] Note: a, 0.2μM; b, 0.8μM
[0122] Table 3 Relationship between the number of A at the 3' end (before poly-G) of type A CpG palindrome and aggregation and activity
[0123]
[0124]
[0125] Note: b, 0.8 μM
[0126] Table 4 Relationship between the number of T at the 3' end (before poly-G) of type A CpG palindrome and aggregation and activity
[0127] serial number The number of T Aggregate (%) Activity (IFN-α, pg / mL) AM1012-05 0 0.7 <![CDATA[478.4±44.9 b ]]> AM1012-05-20 2 1.7 <![CDATA[531.7±11.9 b ]]> AM1012-05-21 5 1.26 <![CDATA[458.1±17.3 b ]]> AM1012-05-22 10 10.38 <![CDATA[576.6±115.7 b ]]> D19 0 4.94 <![CDATA[345.9±93.1 b ]]> D19-11 2 15.22 <![CDATA[502.3±81.4 b ]]> D19-12 5 20.75 <![CDATA[398.4±38.8 b ]]> D19-13 10 23.56 <![CDATA[228.1±42.6 b ]]> 2216 0 4.21 <![CDATA[435.8±129.6 b ]]> 2216-11 2 11.41 <![CDATA[525.5±64.0 b ]]> 2216-12 5 19.68 <![CDATA[455.8±24.3 b ]]> 2216-13 10 44.83 <![CDATA[405.8±192.3 b ]]>
[0128] Note: b, 0.8 μM
[0129] Table 5 Relationship between the number of C at the 3' end (before poly-G) of type A CpG palindrome and aggregation and activity
[0130] serial number The number of C Aggregate (%) Activity (IFN-α, pg / mL) AM1012-05 0 0.7 <![CDATA[478.4±44.9 b ]]> AM1012-05-23 2 0.84 <![CDATA[399.3±108.4 b <!-- 14 -->]]> AM1012-05-24 5 5.75 <![CDATA[258.4±49.6 b ]]> AM1012-05-25 10 0 <![CDATA[10.5±1.4 b ]]> D19 0 4.94 <![CDATA[345.9±93.1 b ]]> D19-14 2 6.42 <![CDATA[552.0±134.2 b ]]> D19-15 5 3.74 <![CDATA[49.0±2.4 b ]]> D19-16 10 0 <![CDATA[45.4±1.0 b ]]> 2216 0 4.21 <![CDATA[435.8±129.6 b ]]> 2216-14 2 2.54 <![CDATA[150.5±39.3 b ]]> 2216-15 5 6.5 <![CDATA[118.8±44.7 b ]]> 2216-16 10 0 <![CDATA[15.2±0.5 b ]]>
[0131] Note: b, 0.8 μM
[0132] Example 3: Cytokine release after stimulation of NK-92 cells with different CpG ODNs
[0133] (1) NK-92 cells are human NK cell lines that express TLR-9 receptors intracellularly and are often used to evaluate the function of TLR-9 agonists. In this experiment, NK-92 cells were cultured and expanded to the required cell mass according to the cell instructions and resuspended in a certain amount of complete culture medium;
[0134] (2) Take 20 μL of cell suspension, mix it with trypan blue at a ratio of 1:1, and count it using a cell counter to determine cell viability and cell density;
[0135] (3) 2.5×10 5Cells / well were plated in 96-well plates, and CpG samples (sequences in Table 1) of different concentrations were added to each well, with 3 replicates per group;
[0136] (4) Place in a 37°C, 5% CO2 incubator for 72 hours;
[0137] (5) After the cell culture was completed, the mixture was centrifuged at 1200 rpm for 5 min, 100 μL of the cell-free supernatant was collected, and the secretion of IFN-γ in the supernatant was detected according to the instructions of the ELISA kit.
[0138] The experimental results are as follows Figure 1 As shown in Table 1 of the present invention, the CpG sequences designed can effectively stimulate the secretion of IFN-γ by NK cells, among which AM1012-03, AM1012-04, AM1012-05, AM1012-17, and AM1012-35 sequences have particularly significant NK stimulation effects. In addition, the stimulation effect of AM1012-05 is better than that of E41-1 and E41-2, and significantly better than that of E41-3. Figure 2 D in Figure 2 The results of the E experiment in show that increasing or decreasing the number of Gs on both sides of the core sequence of the present invention will change the immunostimulatory activity of the sequence. When the number of Gs on both sides of the core sequence reaches a specific number, the sequence can exert the best immune activation effect.
[0139] Example 4: Detection of the effect of CpG sequences on the secretion of IFN-γ, IL-6, and TNF-α based on SD rat spleen cells
[0140] (1) Take a certain amount of 100 μM AM1012-05, E41-1, E41-2, and E41-3 solution, prepare a certain concentration of stock solution with RPMI 1640 complete medium, and then dilute it with complete medium at a ratio of 4 times to prepare test samples of different concentrations;
[0141] (2) Obtain an appropriate amount of fresh SD rat spleen cells;
[0142] (3) According to 1×10 6 cells / well were plated in 96-well plates, and AM1012-05 samples of different concentrations were added to each well. The final concentrations were 3.2 μM, 0.8 μM, and 0.2 μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0143] (4) Place in a 37°C, 5% CO2 incubator for 16 h or 72 h;
[0144] (5) Centrifugation to collect the supernatant;
[0145] (6) Detect IFN-γ, IL-6, and TNF-α according to the ELISA test instructions for different detection indicators.
[0146] The experimental results are as follows Figure 2 As shown in the figure, the designed AM1012-05 and E41-1, E41-2, and E41-3 can significantly stimulate the secretion of IFN-γ, TNF-α, and IL-6 in SD rat spleen cells, and have a good dose-dependency. However, the immune activation ability of AM1012-05 on SD rat spleen cells is significantly better than that of E41-1, E41-2, and E41-3. Figure 2 From the C in the figure, we can see that AM1012-05 has a better immune activation ability.
[0147] Example 5: Effect of AM1012-05 sequence on NK-92 cytokine release
[0148] (1) preparing NK-92 cells to a desired cell volume as described in Example 3, and resuspending them in a certain amount of complete culture medium;
[0149] (2) Take 20 μL of cell suspension, mix it with trypan blue at a ratio of 1:1, and count it using a cell counter to determine cell viability and cell density;
[0150] (3) AM1012-05 sample was prepared into a 100 μM solution in PBS;
[0151] (4) Take a certain amount of 100 μM AM1012-05 solution, prepare it into a certain concentration of stock solution with complete culture medium, and then dilute the AM1012-05 solution with complete culture medium at a ratio of 2 to prepare AM1012-05 test samples of different concentrations;
[0152] (5) 2.5×10 5 cells / well were plated in 96-well plates, and AM1012-05 samples of corresponding concentrations were added to each well. The final concentrations were 20μM, 10μM, 5μM, 2.5μM, 1.25μM, 0.63μM, 0.31μM, 0.16μM, and 0.08μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0153] (6) Place in a 37°C, 5% CO2 incubator for 72 hours;
[0154] (7) After the cell culture was completed, the mixture was centrifuged at 1200 rpm for 5 min, 100 μL of the cell-free supernatant was collected, and the secretion of IFN-γ in the supernatant was detected according to the instructions of the ELISA kit.
[0155] The experimental results are as follows Figure 3As shown, the AM1012-05 sequence can effectively stimulate the secretion of IFN-γ in NK-92 cells, and has a good dose-dependency. Since NK-92 cells express TLR9, this experiment also verifies that the immune activation activity of AM1012-05 is stimulated by binding to TLR9.
[0156] Example 6: Detection of the effect of AM1012-05 on the secretion of IL-6, IFN-γ, TNF-α, IFN-α, etc. based on BALB / c mouse spleen cells
[0157] (1) Take a certain amount of 100 μM AM1012-05 solution, use RPMI 1640 complete medium to prepare a certain concentration of stock solution, then dilute the AM1012-05 solution with complete medium at a ratio of 2 times to prepare AM1012-05 test samples of different concentrations;
[0158] (2) Obtain an appropriate amount of fresh BALB / c mouse spleen cells;
[0159] (3) According to 1×10 6 cells / well were plated in 96-well plates, and AM1012-05 samples of corresponding concentrations were added to each well. The final concentrations were 8μM, 4μM, 2μM, 1μM, 0.5μM, 0.25μM, 0.13μM, 0.06μM, and 0.03μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0160] (4) Place in a 37°C, 5% CO2 incubator for 16 h or 72 h;
[0161] (5) Centrifugation to collect the supernatant;
[0162] (6) Detect IL-6, IFN-γ, TNF-α, and IFN-α according to the ELISA test instructions for different detection indicators.
[0163] The experimental results are as follows Figure 4 As shown, the designed AM1012-05 sequence can effectively stimulate the secretion of cytokines in BALB / c mouse spleen cells in a certain dose-dependent manner.
[0164] Example 7: Detection of the effect of AM1012-05 on the secretion of IL-6, IFN-γ, TNF-α, IFN-α, etc. based on C57BL6 mouse spleen cells
[0165] (1) Take a certain amount of 100 μM AM1012-05 solution, use RPMI 1640 complete medium to prepare a certain concentration of stock solution, then dilute the AM1012-05 solution with complete medium at a ratio of 2 times to prepare AM1012-05 test samples of different concentrations;
[0166] (2) Obtain an appropriate amount of fresh C57BL6 mouse spleen cells;
[0167] (3) According to 1×10 6 cells / well were plated in 96-well plates, and AM1012-05 samples of corresponding concentrations were added to each well. The final concentrations were 8μM, 4μM, 2μM, 1μM, 0.5μM, 0.25μM, 0.13μM, 0.06μM, and 0.03μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0168] (4) Place in a 37°C, 5% CO2 incubator for 16 h or 72 h;
[0169] (5) Centrifugation to collect the supernatant;
[0170] (6) Detect IL-6, INF-γ, TNF-α, and IFN-α according to the ELISA test instructions for different detection indicators.
[0171] The experimental results are as follows Figure 5 As shown, the designed AM1012-05 sequence can effectively stimulate the secretion of cytokines in C57BL6 mouse spleen cells in a certain dose-dependent manner.
[0172] Example 8: Detection of the effect of AM1012-05 on IFN-α, IFN-γ, TNF-α, and CXCL-10 mRNA transcription based on cotton rat spleen cells
[0173] (1) Take a certain amount of 100 μM AM1012-05 solution, use RPMI 1640 complete medium to prepare a certain concentration of stock solution, then dilute the AM1012-05 solution with complete medium at a ratio of 2 times to prepare AM1012-05 test samples of different concentrations;
[0174] (2) obtaining an appropriate amount of frozen cotton rat spleen cells;
[0175] (3) According to 5×10 6 Cells / well were plated in 6-well plates, and different concentrations of AM1012-05 samples were added to each well. The final concentrations were 0.2 μM, 0.8 μM, and 3.2 μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0176] (4) Place in a 37°C, 5% CO2 incubator for 3 h;
[0177] (5) Collect cells, extract total RNA from samples according to the instructions of the RNA total extraction kit, and measure the total RNA concentration using Nanodrop;
[0178] (6) Reverse transcribe RNA into cDNA according to the instructions of the reverse transcription kit;
[0179] (7) Analyze the expression levels of relevant cytokines in each sample according to the instructions of the RT-qPCR kit.
[0180] The experimental results are as follows Figure 6 As shown in the figure, the designed AM1012-05 sequence can effectively stimulate the secretion of immune-related cytokines in cotton rat spleen cells, and has a good dose-dependency. Cotton rats are a commonly used animal model for respiratory syncytial virus infection, which lays the foundation for the evaluation of AM1012-05 against respiratory syncytial virus using cotton rats.
[0181] Example 9: Detection of the effect of AM1012-05 on IFN-α and CXCL-10 mRNA transcription based on SD rat spleen cells
[0182] (1) Take a certain amount of 100 μM AM1012-05 solution, use RPMI 1640 complete medium to prepare a certain concentration of stock solution, then dilute the AM1012-05 solution with complete medium at a ratio of 2 times to prepare AM1012-05 test samples of different concentrations;
[0183] (2) Obtain an appropriate amount of fresh rat spleen cells;
[0184] (3) According to 5×10 6 Cells / well were plated in 6-well plates, and AM1012-05 samples of different concentrations were added to each well, with 3 replicates per group, and a PBS blank control well was set up at the same time;
[0185] (4) Place in a 37°C, 5% CO2 incubator for 3 h;
[0186] (5) Collect cells, extract total RNA from samples according to the instructions of the RNA total extraction kit, and measure the total RNA concentration using Nanodrop;
[0187] (6) Reverse transcribe RNA into cDNA according to the instructions of the reverse transcription kit;
[0188] (7) Analyze the expression levels of relevant cytokines in each sample according to the instructions of the RT-qPCR kit.
[0189] The experimental results are as follows Figure 7 As shown, the designed AM1012-05 sequence can effectively stimulate the transcription of IFN-α and CXCL-10 mRNA in SD rat splenocytes with good dose dependence.
[0190] Example 10: Detection of the effect of AM1012-05 on the secretion of IFN-γ, IL-6 and TNF-α based on SD rat spleen cells
[0191] (1) Take a certain amount of 100 μM AM1012-05 solution, use RPMI 1640 complete medium to prepare a certain concentration of stock solution, then dilute the AM1012-05 solution with complete medium at a ratio of 2 times to prepare AM1012-05 test samples of different concentrations;
[0192] (2) Obtain an appropriate amount of fresh SD rat spleen cells;
[0193] (3) According to 1×10 6 cells / well were plated in 96-well plates, and AM1012-05 samples of corresponding concentrations were added to each well. The final concentrations were 20μM, 10μM, 5μM, 2.5μM, 1.25μM, 0.625μM, 0.3125μM, 0.1562μM, and 0.087μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0194] (4) Place in a 37°C, 5% CO2 incubator for 16 h or 72 h;
[0195] (5) Centrifugation to collect the supernatant;
[0196] (6) Detect IFN-γ, IL-6, and TNF-α according to the ELISA test instructions for different detection indicators.
[0197] The experimental results are as follows Figure 8 As shown, the designed AM1012-05 sequence can effectively stimulate the secretion of IFN-γ, IL-6, and TNF-α in SD rat spleen cells, and has good dose dependence. SD rats are a commonly used animal model for preclinical evaluation of drug toxicity. Combined with the data of Example 9, the experimental results lay the foundation for the safety evaluation experiment of AM1012-05 using SD rats.
[0198] Example 11: Detection of the effect of AM1012-05 on the secretion of IFN-α, IFN-γ, IFN-λ, IL-6, TNF-α, and CXCL-10 based on beagle PBMC
[0199] (1) Take a certain amount of 100 μM AM1012-05 solution and prepare it into a certain concentration of stock solution with RPMI 1640 complete medium, then dilute the AM1012-05 solution with complete medium at a ratio of 4 times to prepare AM1012-05 test samples of different concentrations;
[0200] (2) Obtain an appropriate amount of fresh beagle PBMCs;
[0201] (3) According to 5×10 6 Cells / well were plated in 6-well plates, and different concentrations of AM1012-05 samples were added to each well. The final concentrations were 0.2 μM, 0.8 μM, and 3.2 μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0202] (4) Place in a 37°C, 5% CO2 incubator for 6 h;
[0203] (5) Collect cells, extract total RNA from samples according to the instructions of the RNA total extraction kit, and measure the total RNA concentration using Nanodrop;
[0204] (6) Reverse transcribe RNA into cDNA according to the instructions of the reverse transcription kit;
[0205] (7) Analyze the expression levels of relevant cytokines in each sample according to the instructions of the RT-qPCR kit.
[0206] The experimental results are as follows Fig. 9 As shown in the figure, the designed AM1012-05 sequence can effectively stimulate the secretion of immune-related cytokines in beagle PBMC, and has a good dose-dependency. Beagles are a commonly used animal model for preclinical evaluation of drug toxicity, which lays the foundation for the safety evaluation experiment of AM1012-05 using beagles. In addition, the efficacy of AM1012-05 on beagle PBMC also suggests its great potential for use as a pet vaccine adjuvant or in anti-infection.
[0207] Example 12: Detection of the effects of AM1012-05 and related sequences on the secretion of IFN-α, IFN-γ, IFN-λ, TNF-α, IL-6, and CXCL-10 based on healthy human PBMC cells
[0208] (1) Take a certain amount of 100 μM AM1012-05 and related sequence solutions, prepare a certain concentration of stock solution with RPMI 1640 complete medium, and then dilute the AM1012-05 and related sequence solutions with complete medium at a ratio of 4 times to prepare test samples of different concentrations;
[0209] (2) Obtain an appropriate amount of cryopreserved healthy human PBMC cells;
[0210] (3) According to 2×10 5 Cells / well were plated in 96-well plates, and samples of different concentrations were added to each well, with 3 replicates per group, and a PBS blank control well was set up at the same time;
[0211] (4) Place in a 37°C, 5% CO2 incubator for 16 h;
[0212] (5) Centrifugation to collect the supernatant;
[0213] (6) Detect cytokines according to the ELISA test instructions.
[0214] The experimental results are as follows Fig.10 As shown, AM1012-05 can stimulate IFN-α ( Fig.10 Middle A), IFN-γ( Fig.10 Middle B), IFN-λ( Fig.10 C), TNF-α( Fig.10 D), IL-6 ( Fig.10 Middle E), CXCL-10 ( Fig.10 In addition, AM1012-05 and related sequences significantly activated IFN-α better than CpG 2216 and D19 ( Fig.10 G). AM1012-05 significantly promotes IFN-α secretion, with an EC50 of 0.19 μM and an optimal stimulation concentration of 0.5 μM. 1 μM AM1012-05 also significantly promotes IFN-γ secretion and 0.25 μM AM1012-05 significantly promotes IFN-λ secretion, which shows that AM1012-05 has a very strong antiviral potential. AM1012-05 can stimulate healthy human PBMC to secrete TNF-α, and has a good dose-dependency, but its ability to stimulate TNF-α is significantly lower than its ability to stimulate IFN-α (EC50 is 0.19 and 2.46 μM, respectively), which shows that AM1012-05 can exert high-efficiency antiviral activity (IFN-α, IFN-γ, IFN-λ) at a lower dose without triggering inflammatory responses represented by TNF-α and IL-6.
[0215] Example 13: Serum stability test of CpG ODN
[0216] This experiment uses polyacrylamide gel (PAGE) electrophoresis to explore the degree of sequence damage caused by fetal bovine serum (FBS). The specific operation is as follows: AM1012-05, AM1012-03, E41-2, and E41-3 are respectively prepared into 25OD / mL aqueous solutions, 10μL of 10% FBS is added, and incubated in a constant temperature water bath at 37°C for a certain period of time. After the incubation, the degree of sequence damage is detected by polyacrylamide gel (PAGE) electrophoresis. The results are as follows: Fig.11The results show that AM1012-05 (1205) remains stable in 25% fetal bovine serum solution, E41-3 is most degraded (4103), AM1012-03 (1203) and E41-2 (4102) are in the middle of degradation, and AM1012-05 (1205) is least degraded. Therefore, compared with E41-2 and E41-3, the AM1012-05 sample has better stability.
[0217] Example 14: Analysis of the aggregation state distribution of different CpG ODN aggregates
[0218] Take 3 mg of AM1012-03, E41-2, E41-3, and AM1012-05 and add them into 1 ml of deionized water to obtain a clear solution.
[0219] The above four solutions were evenly divided into two groups: one group was placed at room temperature, and the other group was placed in a 95°C water bath and heated for 30 minutes and then quickly cooled to below 4°C with ice water. Take the above eight solutions and add equal amounts of 800mM sodium chloride solution to make the samples in a 400mM sodium ion environment. After incubation for 24 hours, centrifuge and separate the precipitate. Redissolve the precipitate in water to prepare a clear solution. Test the aggregation distribution of each sample by polyacrylamide gel (PAGE) electrophoresis.
[0220] The electrophoresis results are as follows Fig.12 As shown. The M in the figure indicates 20, 40, and 80 base markers. Lanes 1, 2, 3, and 4 correspond to samples of AM1012-03, E41-2, E41-3, and AM1012-05 placed at room temperature, and lanes 5, 6, 7, and 8 correspond to samples of AM1012-03, E41-2, E41-3, and AM1012-05 that were heated in a 95°C water bath for 30 minutes and then quickly cooled to below 4°C with ice water. The left picture shows the electrophoresis results after the precipitate was dissolved in water for 2 hours, and the right picture shows the electrophoresis results of the same sample solution after being placed for 24 hours.
[0221] Literature reports indicate that the polyG sequence at the 5' or 3' end of type A CpG will cause type A CpG to form aggregates with the assistance of metal ions, and the accumulation of aggregates will cause precipitation. The controllable degree of aggregation is a key indicator for evaluating the drugability of type A CpG (Kerkmann et al., J Biol Chem. 2005 Mar 4; 280(9): 8086-93.).
[0222] In this experiment, all samples incubated in a 400mM sodium ion environment formed a precipitate. After the precipitate was placed back in water, the high-polymer state of type A CpG gradually disintegrated in an environment without metal ions and could be dissolved again. Low-polymer forms such as dimers and tetramers also have a certain solubility in water. Therefore, observing the re-dissolved samples at different time points can maximize the observation of the (low) aggregation distribution of each type A CpG and the trend of change over time.
[0223] For the samples placed at room temperature, the re-dissolved solution of AM1012-03 was mainly tetramers and monomers after 2 hours, and became scattered bands after 24 hours; the re-dissolved solution of E-41-2 was mainly dimers after 2 hours, and still mainly dimers after 24 hours, but tetramers gradually appeared; the re-dissolved solution of E-41-3 showed dimers and polymers (larger than tetramers) after 2 hours, and scattered bands dominated by dimers appeared after 24 hours; in the re-dissolved solution of AM1012-05, most of it was in a monomer state after 2 hours and 24 hours, with only a small number of aggregates.
[0224] For the samples that were heated in a 95℃ water bath for 30 minutes and then quickly cooled to below 4℃ with ice water, the re-dissolved solution of AM1012-03 was mainly tetramers and monomers after 2 hours, and diffuse bands appeared after 24 hours. The re-dissolved solution of E-41-2 was mainly dimers after 2 hours, and still mainly dimers after 24 hours, but tetramers and monomers gradually appeared. The re-dissolved solution of E-41-3 was a collection of multiple aggregation states after 2 hours, and after 24 hours, it showed diffuse bands dominated by monomers and dimers. In the re-dissolved solution of AM1012-05, most of it was in the monomer state after 2 hours and 24 hours, with only a few aggregates.
[0225] From the above results, AM1012-05 is easier to disaggregate back to the monomer state than other A-type CpG monomers under the same conditions. Other A-type CpGs will transform between monomers, dimers, tetramers or other polymer forms. Therefore, in actual formulation applications, as long as the concentration of metal salts is well controlled, AM1012-05 can stably remain in the monomer state. After the formulation enters the human body, under the physiological salt concentration, AM1012-05 can produce the unique polymerization state of A-type CpG and produce drug effects.
[0226] At the same time, CpG 2216 and AM1012-05 were prepared into 0.5 mg / mL solutions with 10 mM phosphate buffer solution, and after standing overnight, the particle size of CpG was measured using a Nicomp Z3000 laser particle size analyzer. After the measurement, the solution was vortexed for 3 minutes and the particle size was measured again. The results are shown in Figure 2. Fig.13The results show that the particle size distribution of CpG 2216 before vortexing is around 2 nm, 75 nm, and 250 nm, while after vortexing, the particle size of CpG 2216 is concentrated around 280 nm. The particle size of AM1012-05 is around 30 nm in a static state, while after vortexing, the particle size of AM1012-05 is concentrated around 2 nm.
[0227] The results of the laser particle size analyzer test showed the aggregation state of CpG in the natural state. In 10mM phosphate buffer solution, AM1012-05 showed a loose aggregation state in a static state. When subjected to mechanical force, the aggregation was opened and became a monomer state. However, CpG 2216 showed a dispersed complex polymer in 10mM phosphate buffer solution, which could not be broken up under the action of mechanical force.
[0228] Fig.13 The results showed that CpG 2216 is a traditional A-type CpG. There is no additional deoxyribonucleotide between the 3' end of the palindrome structure and the 5' end of poly-G, and there is no certain spatial barrier. The energy for forming G-tetrad is reduced, and the aggregates formed are tightly bound and cannot be easily broken up by mechanical force. AM1012-05 has two As inserted between the 3' end of the palindrome structure and the 5' end of poly-G, forming a certain spatial barrier, which increases the energy for forming G-tetrad, making the aggregates relatively difficult to form or relatively loose after forming. Therefore, under natural static conditions, AM1012-03 is in a uniformly distributed aggregation equilibrium state of about 30 nanometers, which significantly improves its drugability compared to traditional A-type CpG.
[0229] Example 15: Secondary structure simulation analysis and comparison of different sequences
[0230] The sequences of CpG 2216, E41-1, AM1012-3, and AM1012-5 were respectively constructed using an online modeling tool ( https: / / rna.urmc.rochester.edu / ) predict the secondary structure, adjust the temperature parameters, and obtain the secondary structure of each sequence under different temperature conditions.
[0231] The specific secondary structure diagram is as follows Figure 14-24As shown. From the comparison of the secondary structures of the four at different temperatures, we can find that CpG 2216 is relatively stable at 4℃-37℃. When the temperature is higher than 40℃, its secondary structure is misfolded, and its biological activity is affected; E41-1 is relatively stable at 0℃-37℃. When the temperature reaches -20℃, local internal hydrogen bonds break. When the temperature is higher than 40℃, its secondary structure is misfolded. Too high or too low temperature will affect its biological activity; AM1012-03 is also relatively stable at 0℃-37℃. When the temperature reaches 0℃, local internal hydrogen bonds break. When the temperature is higher than 40℃, its secondary structure will also be misfolded, thereby affecting its biological activity; AM1012-05 can maintain its constant secondary structure at 0℃-50℃. Only when the temperature is higher than 60℃, local internal hydrogen bonds will break. This indicates that the secondary structure of AM1012-05 sequence is more stable than that of CpG 2216, E41-1 and AM1012-03, which also explains from the structural point of view that the stability and activity of AM1012-05 are better than those of CpG 2216, E41-1 and AM1012-03.
[0232] Example 16: Evaluation of the stimulatory ability of CpG ODN with different aggregation levels on rat splenocytes
[0233] (1) A certain amount of 100 μM CpG ODN solution treated at different temperatures was prepared into a certain concentration of stock solution using RPMI 1640 complete medium, and then the CpG ODN solution was diluted with complete medium at a ratio of 4 times to prepare test samples of different concentrations;
[0234] (2) Obtain an appropriate amount of fresh SD rat spleen cells;
[0235] (3) According to 1×10 6 Cells / well were plated in 96-well plates, and CpG ODN samples of different concentrations were added to each well. The final concentrations were 3.2 μM and 0.8 μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0236] (4) Place in a 37°C, 5% CO2 incubator for 72 h;
[0237] (5) Centrifugation to collect the supernatant;
[0238] (6) Detect IFN-γ according to the ELISA assay instructions for rat IFN-γ.
[0239] The experimental results are as follows Fig.25As shown in the figure, the designed AM1012-05 sequence can still effectively stimulate the secretion of IFN-γ of SD rat spleen cells after high temperature treatment, while the AM1012-03 sequence cannot effectively stimulate the secretion of IFN-γ of SD rat spleen cells after high temperature treatment. Combined with the sequence secondary structure prediction results of Example 15, the high temperature stability of AM1012-05 is much better than CpG 2216, E41, and AM1012-03. This experiment verifies that a stable secondary structure is a prerequisite for the activity of CpG.
[0240] Example 17: Changes in the stability of CpG ODN raw materials prepared by different processes
[0241] The raw materials of E41-2, E41-3 and AM1012-05 were prepared into 2 mg / mL stock solutions and subjected to different process treatments: direct freeze-drying and freeze-drying after heating at 95°C. The dry powders made by different freeze-drying processes were dissolved and then their aggregation degree and related substances were detected by reverse phase HPLC. The proportion of aggregation state of E41-2, E41-3 and AM1012-05 prepared by different processes changed slightly due to different processes. However, the impurities measured in the dry powders of E41-2 and E41-3 prepared by different processes were very different. The impurity levels measured in AM1012-05 prepared by different processes were basically the same. The results showed that the stability of AM1012-05 was better than that of E41-2 and E41-3, and it had better drugability.
[0242] Table 6 Stability analysis of CpG ODN raw materials prepared by different processes
[0243]
[0244] Example 18: pH Screening of AM1012-05 Formulations
[0245] (1) Prepare sodium phosphate buffers of different pH values: pH 6.6, 7.0, 7.2, 7.4, 8.0, and 9.0;
[0246] (2) dissolving AM1012-05 in the above buffer to prepare a 0.35 mg / ml prescription solution;
[0247] (3) Dispense the above prescription solutions into 10 mL vials at a rate of 1.5 mL each, stopper and cap, and place at 50°C in a dark place.
[0248] (4) Samples were collected on days 0, 5, and 10 for testing.
[0249] The experimental results are shown in Table 7, which show that AM1012-05 is easily degraded in a slightly acidic environment. From the perspective of the formulation, it is stable in the pH range of 7.0-9.0.
[0250] Table 7 pH range screening results of samples
[0251]
[0252] Example 19: Selection of buffer for AM1012-05 solution
[0253] Combined with the pH range and common buffer systems of small nucleic acid drugs on the market, phosphate and citrate buffer systems were screened respectively. 2.5 mg / ml was selected as the experimental sample concentration of AM1012-05, and the aqueous solution of AM1012-05 without adding buffer was used as the control. The pH of the sample was controlled to 7.2. The sample was placed at 50°C for 10 days and samples were taken at 0, 5, and 10 days respectively to compare whether the stability of the sample in the two buffer solutions was better than that of the control group; the results showed that compared with the control group, the purity change of the sample with added buffer was significantly reduced, and the various inspection items of the two buffer system samples showed the same trend of change with the extension of the placement time. The experimental results are shown in Table 8. The buffers of the two buffer systems can meet the requirements of the pH buffer of the preparation.
[0254] Table 8 Buffer screening results
[0255]
[0256] Example 20: Range screening of metal ion concentrations in CpG ODN
[0257] Take 5 mg of sodium acetate, sodium dihydrogen phosphate / disodium hydrogen phosphate, magnesium chloride, calcium chloride, potassium chloride, sodium chloride, and 0.25 mg of AM1012-05 to prepare a 200 μl solution sample. Place the test sample in a sealed clean container at 40°C for 30 days and take samples on the 5th, 15th, and 30th days. The test indicators include properties (appearance), solubility of concern, impurities (related substances) and content.
[0258] The test results show that sodium acetate, sodium dihydrogen phosphate / disodium hydrogen phosphate, magnesium chloride, calcium chloride, potassium chloride, and sodium chloride produce precipitation when mixed with AM1012-05 at a ratio of concentration. Therefore, it is necessary to screen out the salt concentration suitable for CpG ODN preparation to ensure the clarity of the preparation solution.
[0259] AM1012-05 was selected and potassium chloride and sodium chloride solutions were added respectively, so that the final concentration of AM1012-05 in the obtained solution was 2 mg / ml and the final concentration of the salt solution was 90 mM. After being placed for 24 hours, AM1012-05 remained clear in the two salt solutions.
[0260] AM1012-05 was selected and magnesium chloride and calcium chloride solutions were added respectively, so that the final concentration of AM1012-05 in the obtained solution was 2 mg / ml and the final concentration of the saline solution was 1.8 mM. After being placed for 24 hours, AM1012-05 remained clear in the two saline solutions.
[0261] Four phosphate buffer solutions (composed of sodium dihydrogen phosphate and sodium dihydrogen phosphate) of 5, 10, 20, and 50 mM were selected as the investigation concentrations (sodium ion concentrations were approximately 9, 18, 36, and 90 mM, respectively), and compared with isotonic (150 mM) PBS (sodium ion concentrations were approximately 179 mM, respectively). 2.5 mg / ml was used as the experimental AM1012-05 concentration, the sample pH was controlled to 7.2, the sample was placed at 50°C for 10 days and sampled at 0, 5, and 10 days, and the stability of the sample was tested to determine the pH buffer concentration; the results are shown in Table 9. Compared with 0 days, the sample was placed at 50°C for 5 days, and the clarity and properties of the sample did not change significantly, and the purity did not differ significantly with the extension of the placement time. However, AM1012-05 under isotonic PBS showed obvious turbidity. Therefore, it is not suitable to prepare AM1012-05 preparations under isotonic (150 mM) PBS salt concentration. Taking into account the pH buffering capacity and the risk of AM1012-05 precipitation, the sodium ion concentration in the solution preparation is selected to be between 0.1-90 mM. The total concentration range of metal ions such as sodium, potassium, magnesium, calcium, zinc, and iron in the CpG ODN solution preparation is between 0.1-90 mM.
[0262] Table 9 Salt buffer concentration screening
[0263]
[0264] Example 21: Selection of isotonicity regulator for AM1012-05 solution
[0265] In solution, sodium chloride is generally used to adjust isotonicity. However, since the formation of type A CpG aggregation is related to the concentration of metal ions in the solution, isotonic sodium chloride solution will cause type A CpG to precipitate from the solution, so other excipients need to be selected as isotonicity regulators.
[0266] Excipients that can be used for isotonicity regulators include glycine, trehalose, mannitol, sucrose, arginine, lysine, histidine, sorbitol, glucose, glycerol, propylene glycol, etc.
[0267] Each tube of the above excipients is prepared into a 200μl solution sample according to 0.25mg AM1012-05 and 5mg excipients. The test sample is placed in a sealed clean container, placed at 40℃ for 30 days and sampled on the 5th, 15th and 30th days. The test indicators include properties (appearance), solubility of concern, impurities (related substances) and content. The test results show that the solutions of sorbitol and glucose mixed with AM1012-05 respectively have abnormal main peaks in the HPLC spectrum, and sorbitol is not compatible with glucose and AM1012-05, and is not suitable as an isotonic regulator in AM1012-05 preparations. Glycine, trehalose, mannitol, sucrose, arginine, lysine, histidine, glycerol, and propylene glycol are compatible with AM1012-05 and can be used as isotonic regulators for AM1012-05.
[0268] AM1012-05 was prepared into a 0.35 mg / ml prescription solution with three isotonic regulators and phosphate buffer. The properties (appearance), clarity, pH, osmotic pressure and purity were tested. The specific prescription is shown in Table 10:
[0269] Table 10 AM1012-05 prescription preparation
[0270]
[0271]
[0272] The experimental results are shown in Table 11, which show that the three formulations of AM1012-05 can obtain clear solutions, and the pH, osmotic pressure and purity all meet the preparation requirements.
[0273] Table 11AM1012-05 Test results of three prescriptions
[0274] Types of regulators Mannitol glycerin Propylene glycol Characteristics Colorless clear liquid Colorless clear liquid Colorless clear liquid Clarity ≤0.5 ≤0.5 ≤0.5 pH 7.33 7.27 7.31 Osmol / kg 324 284 296 purity% 96.4 96.33 96.4
[0275] Example 22: Preparation of AM1012-05 formulation and freeze-dried formulation development
[0276] AM1012-05 was dissolved in deionized water, and mannitol (lyophilization protective agent) and pH adjuster (sodium hydrogen phosphate + citric acid) were added to prepare a solution containing 1 mg / mL AM1012-05, 5% mannitol, and 50 mM sodium hydrogen phosphate + citric acid.
[0277] Fill 0.2 mL of the above solution into a 2 mL vial, transfer it to a freeze dryer with a half stopper and freeze-dry it at -30°C. After freeze-drying, the sample is stoppered and capped to obtain a white freeze-dried powder. The freeze-dried preparation can be immediately reconstituted after adding 1 mL of water for injection. The freeze-dried preparation of AM1012-05 can store AM1012-05 in solid form, which is beneficial to the stability of the main drug and is an alternative preparation for the liquid preparation of AM1012-05.
[0278] Example 23: Selection of other excipients for AM1012-05 solution
[0279] In the solution preparation of CpG ODN, in addition to the isotonicity regulator and the pH buffer system, other excipients may be added to provide corresponding functions.
[0280] Other optional excipients include surfactants (such as Pluronic F127, Pluronic F68, Tween 20, Tween 80), preservatives (such as benzalkonium chloride), metal chelators (disodium edetate), viscosity regulators (hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium citrate), methyl beta-cyclodextrin, hydroxypropyl beta-cyclodextrin, antioxidants (ascorbic acid), etc.
[0281] In this test, 5 mg of Pluronic F127, Pluronic F68, Tween 20, Tween 80, ascorbic acid and 0.25 mg of AM1012-05 were prepared into 200 μl solution samples. The test samples were placed in a sealed clean container at 40°C for 30 days and samples were taken on the 5th, 15th and 30th days. The test indicators include properties (appearance), solubility of concern, impurities (related substances) and content.
[0282] At the same time, benzalkonium chloride, disodium edetate, sodium citrate, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methyl beta-cyclodextrin, and hydroxypropyl beta-cyclodextrin were prepared according to the concentrations in Table 12, and AM1012-05 was added to prepare a 0.4 mg / mL prescription solution, and the pH was adjusted to 7.0-7.5. The test sample was placed in a sealed clean container at 40°C for 30 days and sampled on the 5th, 15th, and 30th days. Test indicators: properties (appearance), solubility of concern, impurities (related substances) and content.
[0283] Table 12 Excipients
[0284]
[0285]
[0286] The test results show that the mixture of ascorbic acid and AM1012-05 will cause the degradation of AM1012-05, so it is not suitable for the preparation of AM1012-05. The mixture of hydroxypropyl beta-cyclodextrin and AM1012-05 was tested by HPLC method, and the corresponding main peak of AM1012-05 showed abnormal peak shape, so it is also not suitable for the preparation of AM1012-05.
[0287] Pluronic F127, Pluronic F68, Tween 20, Tween 80, benzalkonium chloride, disodium edetate, sodium citrate, hypromellose, sodium carboxymethyl cellulose, and methyl-beta-cyclodextrin are compatible with AM1012-05 and can be used as excipients for AM1012-05 related preparations.
[0288] Example 24: Preparation of PLGA nanoformulation of CpG ODN
[0289] (1) Dissolve 100 mg of PLGA in 1.25 mL of dichloromethane (oil phase).
[0290] (2) Prepare a 12 mg / ml AM1012-05, 1% PVA solution. (Aqueous phase 1)
[0291] (3) Prepare 4 ml of 2.5% PVA solution. (Aqueous phase 2)
[0292] (4) The oil phase and the water phase 1 are homogenously mixed to form colostrum, and then the colostrum is added to the water phase 2 and homogenized using a homogenizer to form a double emulsion.
[0293] (5) The formed emulsion was slowly added into a 1% PVA aqueous solution (external aqueous phase) and stirred for 4 h to evaporate the dichloromethane.
[0294] (6) Centrifuge the solution in step 5 at 500 g for 5 minutes to remove large particles of microspheres and collect the supernatant.
[0295] (7) Centrifuge the supernatant in step 6 at 10,000 g for 10 minutes, collect the solid, and wash it three times with deionized water or ultrapure water to obtain a PLGA microsphere product.
[0296] The obtained PLGA microsphere product was tested by Nicomp Z3000 laser particle size analyzer, and the particle size can be controlled within 500 nanometers (such as Fig.26 shown).
[0297] Example 25: Preparation of Chitosan Nanoformulation of CpG ODN
[0298] (1) Prepare 0.5 mg / ml chitosan (molecular weight 200,000) solution and adjust the pH to 5.6
[0299] (2) Prepare 50 μg / ml AM1012-05 solution
[0300] (3) 10 ml of AM1012-05 solution was added dropwise to 10 ml of chitosan solution and stirred for 1 minute.
[0301] The AM1012-05 chitosan nanoparticles prepared in this experiment were tested by a laser particle size analyzer and a dynamic light scattering particle size analyzer, and the particle size can be controlled at about 150 nanometers (e.g. Fig. 27 shown).
[0302] Example 26: Preparation of CpG ODN lipid nanoparticle formulation
[0303] CpG ODN lipid nanoparticles (LNP) are synthesized by selecting different types of lipids, mixing and self-assembling in a certain proportion to encapsulate CpG into nanoparticles. Lipids include ionizable cationic liposomes, neutral phospholipids, sterol lipids and PEGylated phospholipids. The specific preparation process is as follows:
[0304] (1) SM-102, DSPC, cholesterol, and DMG-PEG (2000) were dissolved in ethanol at a ratio of 50:10:38.5:1.5.
[0305] (2) Take 0.25 ml of the above lipid solution, add 0.75 ml of 80 μg / ml AM1012-05, 50 mM citrate buffer solution, vortex mix, and transfer to a hand-push liposome extruder.
[0306] (3) Mix by rapid pipetting and squeezing through an extruder and let the mixture stand for 10 minutes.
[0307] (4) Using a 200KD dialysis bag, add an equal volume of 50mM citrate buffer solution to the mixture, seal it, and place it in 50ml PBS solution for dialysis.
[0308] The AM1012-05 lipid nanoparticles prepared in this experiment were tested by Nicomp Z3000 laser particle size analyzer, and the particle size can be controlled to be around 100 nanometers (e.g. Fig.28 shown).
[0309] Example 27: Preparation of CpG ODN Preparation of PLGA Nanoparticles as an Immunoadjuvant
[0310] (1) Dissolve 100 mg of PLGA in 1.25 mL of dichloromethane (oil phase).
[0311] (2) Add AM1012-05 and antigen protein (S1 protein) to a 1% PVA solution to prepare a solution containing 10 mg / ml AM1012-05 and 10 mg / ml S1 protein. (Aqueous phase 1)
[0312] (3) Prepare 4 ml of 2.5% PVA solution. (Aqueous phase 2)
[0313] (4) The oil phase and the water phase 1 are homogenously mixed to form colostrum, and then the colostrum is added to the water phase 2 and homogenized using a homogenizer to form a double emulsion.
[0314] (5) The formed emulsion was slowly added into a 1% PVA aqueous solution (external aqueous phase) and stirred for 4 h to evaporate the dichloromethane.
[0315] (6) Centrifuge the solution in step 5 at 500 g for 5 minutes to remove large particles of microspheres and collect the supernatant.
[0316] (7) Centrifuge the supernatant from step 6 at 10,000 × g for 10 minutes to collect the solids. Wash three times with deionized water or ultrapure water to obtain PLGA microspheres.
[0317] The PLGA microsphere vaccine product encapsulating AM1012-05 and antigen protein obtained in this experiment was tested by Nicomp Z3000 laser particle size analyzer, and the particle size can be controlled within 500 nanometers (such as Fig.29 shown).
[0318] Example 28: Compatibility study of excipients in topical preparations of CpG ODN
[0319] Excipients that can be used in topical preparations are classified into oil phase, thickeners, gelling agents, emulsifiers, solvents, and penetration enhancers. The oil phase includes glyceryl behenate, liquid paraffin, vaseline, medium chain triglycerides and cocoyl caprylic and capric acid esters; the thickener includes glyceryl monostearate, glyceryl mono- and distearate, and cetostearyl alcohol; the gelling agent includes hydroxypropyl methylcellulose, xanthan gum, carbomer, sodium carboxymethyl cellulose, and poloxamer 407; the emulsifier includes stearic acid polyoxyl (40) fat, polyethylene glycol cetearyl alcohol ether, Tween 60, poloxamer 188, oleoyl polyoxyethylene glyceride, polyethylene glycol-7 stearate, caprylic and capric macrogol glyceride, sodium lauryl sulfate, propylene glycol monofatty acid ester, polyglyceryl oleate, and propylene glycol laurate; the solvent includes glyceryl triacetate and propylene glycol; the penetration enhancer includes isopropyl myristate, propylene glycol, caprylic and capric macrogol glyceride, polyglyceryl oleate, and propylene glycol laurate.
[0320] After the gel excipients are prepared into an aqueous solution of appropriate concentration, they are mixed with AM1012-05 to form a 3 mg / g gel solution. Other excipients are mixed with API in a one-to-one ratio to form a 3 mg / g mixture. The samples are placed in a 40°C incubator and samples are taken at 5, 15, and 30 days to test the content and related substances. The results showed that the excipients compatible with AM1012-05 were: oil phase including glyceryl behenate, liquid paraffin, petrolatum, medium chain triglycerides, cocoyl caprylic and capric acid; thickeners including glyceryl mono- and distearate; gelling agents including hydroxypropyl methylcellulose, carbomer, xanthan gum, sodium carboxymethyl cellulose, and poloxamer 407; emulsifiers including macrogol cetearyl alcohol ether, poloxamer 188, oleoyl polyoxyethylene glyceride, macrogol-7 stearate, caprylic and capric macrogol glyceride, sodium lauryl sulfate, propylene glycol monofatty acid ester, polyglyceryl oleate, and propylene glycol laurate; solvents including propylene glycol; penetration enhancers including isopropyl myristate, propylene glycol, and polyglyceryl oleate.
[0321] Example 29: Preparation of CpG ODN topical ointment preparation
[0322] Weigh AM1012-05, add deionized water to dissolve, and prepare API solution. Weigh appropriate amounts of vaseline and liquid paraffin, place in an 80°C water bath and heat until molten. Add the API solution to the molten oil phase, homogenize at 70-80°C for 10 minutes, cool to 65°C~70°C for packaging. The content of AM1012-05 in the final preparation is 1 mg / g. The ratio of vaseline to liquid paraffin is determined based on physical evaluation, and the ratio of vaseline can be selected between 100%-50%.
[0323] Example 30: Preparation of external gel preparation of CpG ODN
[0324] Prepare Carbomer 974 aqueous solution (2%), 10% triethanolamine and AM1012-05 aqueous solution. Dilute 2% Carbomer 974 aqueous solution to 0.7% concentration, add 10% triethanolamine to adjust pH to 7.0, dissolve phenoxyethanol in propylene glycol, add to the gel, stir and mix, then add API aqueous solution, stir and mix. Add 10% triethanolamine dropwise again to adjust to appropriate pH, make up to volume, stir and mix, and dispense.
[0325] The concentration and type of carbomer used to prepare the gel can be adjusted according to the viscosity requirements, such as carbomer 971, 980, 981, etc. In addition to triethanolamine solution, the neutralizer can also use sodium hydroxide, aminomethyl propanol, tromethamine, tetra-2-hydroxypropyl ethylenediamine, etc. In addition to phenoxyethanol, the preservative can also use parabens and cresol preservatives.
[0326] Example 31: Preparation of CpG ODN topical emulsion
[0327] (1) Oil phase: Place 15 g of vaseline, 6 g of liquid paraffin and 7.2 g of glyceryl mono- and distearate in a container, heat to 70°C, and stir to melt. Keep the molten oil phase at 70°C and stir at a low speed.
[0328] (2) Water phase: Heat 59.5 g of deionized water to 70° C. in a container, and add 1.8 g of polyethylene glycol cetearyl alcohol ether and dissolve.
[0329] (3) Emulsion preparation: Transfer the molten oil phase in step 1 to the water phase container at 70°C while mixing at a speed of 10 rpm.
[0330] (4) After the transfer is completed, start the homogenizer and homogenize for 10 minutes, with the temperature controlled at 65°C to 70°C.
[0331] (5) Stop the homogenizer, set the stirrer to 50°C, and cool the emulsion to 50°C.
[0332] (6) Drug solution: 30 mg of AM1012-05 was dissolved in 10.5 g of deionized water and the temperature was maintained at 50°C.
[0333] (7) The drug solution in step 6 was transferred to the emulsion in step 5, and the temperature was 50°C during stirring.
[0334] (8) Start the homogenizer, mix and homogenize for 10 minutes, and at the same time add 10% sodium hydroxide solution to adjust the pH to 7.5.
[0335] (9) When the emulsion is cooled to 25°C, the prepared emulsion is packaged to finally obtain 100 g of AM1012-05 emulsion containing 0.3 mg / g.
[0336] The oil phase, thickener and emulsifier used in the emulsion can be replaced by excipients that have passed the excipient compatibility test. The emulsion can also be added with a penetration enhancer excipient that has passed the excipient compatibility test.
[0337] Example 32: Preparation of vaccine with CpG as adjuvant
[0338] In this example, the S1 protein of the new coronavirus is used as a model antigen, and CpG is used as an adjuvant to prepare a vaccine.
[0339] (1) Under sterile conditions, take 50 μL of SARS-CoV-2 S1 protein (2 mg / ml PBS solution) and dilute to 250 μL with PBS;
[0340] (2) Prepare a 2 mg / mL solution of AM1012-05 or CpG 1018;
[0341] (3) Add 250 μL of the solution from step (2) to the solution from step (1) and mix well.
[0342] Example 33: Preparation of vaccine with adjuvant system (aluminum adjuvant + CpG)
[0343] In this example, the S1 protein of the new coronavirus was used as a model antigen to prepare a vaccine with an adjuvant system (aluminum adjuvant + CpG)
[0344] Preparation of vaccines with aluminum hydroxide + CpG as adjuvant:
[0345] (1) Take 50 μL of SARS-CoV-2 S1 protein (2 mg / ml PBS solution);
[0346] (2) adding 50 μL of aluminum hydroxide gel adjuvant (2%) to the solution in step (1);
[0347] (3) Add 350 μL of PBS solution to the solution in step (2) and mix well;
[0348] (4) Take 50 μL of 2 mg / mL AM1012-05 solution, add it to the above solution, and mix well to allow the adjuvant to effectively adsorb the antigen.
[0349] Preparation of vaccines with aluminum phosphate + CpG as adjuvant:
[0350] (1) Take 50 μL of SARS-CoV-2 S1 protein (2 mg / ml PBS solution);
[0351] (2) adding 100 μL of aluminum phosphate gel adjuvant (0.5%) to the solution in step (1);
[0352] (3) Add 300 μL of PBS solution to the solution in step (2) and mix well;
[0353] (4) Take 50 μL of 2 mg / mL AM1012-05 solution, add it to the above solution, and mix well to allow the adjuvant to effectively adsorb the antigen.
[0354] Example 34: Effect of AM1012-05 solution preparation on IFN-γ release from NK-92 cells
[0355] (1) preparing NK-92 cells to a desired cell volume as described in Example 3, and resuspending them in a certain amount of complete culture medium;
[0356] (2) Take 20 μL of cell suspension, mix it with trypan blue at a ratio of 1:1, and count it using a cell counter to determine cell viability and cell density;
[0357] (3) Take a certain amount of AM1012-05 solution sample, prepare it into a mother solution with complete culture medium, and then dilute the AM1012-05 solution with complete culture medium at a ratio of 4 times to prepare AM1012-05 test samples of different concentrations;
[0358] (4) 2.5×10 5 cells / well were plated in 96-well plates, and AM1012-05 samples of different concentrations were added to each well. The final concentrations were 3.2 μM, 0.8 μM, and 0.2 μM, respectively. There were 3 replicates in each group, and a PBS blank control well was set at the same time;
[0359] (5) Place in a 37°C, 5% CO2 incubator for 72 hours;
[0360] (6) After the cell culture was completed, centrifuge at 1200 rpm for 5 min, collect 100 μL of the cell-free supernatant, and detect the secretion of IFN-γ in the supernatant according to the instructions of the ELISA kit;
[0361] The experimental results are as follows Fig.30 As shown, the solution preparation sample of AM1012-05 has a stimulating effect on the secretion of IFN-γ by NK cells that is equivalent to that of AM1012-05, and the blank preparation sample has no stimulating effect on NK-92 cells, which indicates that the solution preparation prescription used in the present invention has a good match with AM1012-05 and will not affect the immune cell activation function of AM1012-05.
[0362] Example 35: Effects of AM1012-05 on the immune system of C57BL6 mice after a single nasal administration
[0363] In C57BL6 mice, the immune activation effect of AM1012-05 on the respiratory tract of mice was evaluated by nasal administration. The experiment was divided into two groups. Each mouse in the drug administration group was given AM1012-05 100μg (25μL / nostril, PBS dissolved drug), and the negative control group was given PBS 50μL (25μL / nostril). The experiment was terminated 24h after the drug administration, and samples (lungs, spleen) were collected to analyze the changes in various immune indicators by RT-qPCR.
[0364] The experimental results are as follows Fig.31As shown in the figure, it can be seen that AM1012-05 can effectively stimulate the expression of IFN-α, IFN-γ and CXCL-10 in the lungs and spleens of mice. And the degree of cytokine activation of the spleen by AM1012-05 is far less significant than that of the lungs (IFN-α and IFN-γ are about 4% of the lungs; CXCL-10 is about 1.5% of the lungs). This may be due to the fact that this experiment was administered by nasal drops, and only a very small amount of AM1012-05 entered the spleen cells through the blood circulation. This result indirectly reflects that the systemic bioavailability of AM1012-05 is very low after nasal administration. At the same time, the dosage of 100μg / mouse did not produce obvious toxic side effects on mice.
[0365] Example 36: Observation of respiratory immune indicators in mice after nasal administration of different doses of AM1012-05
[0366] In C57BL6 mice, the immune activation ability of AM1012-5 at different dosages and different detection time points was evaluated by nasal administration. Each mouse was given AM1012-05 10μg, 50μg, and 100μg (25μL / nostril, PBS dissolved drug) in the three dosage groups, PBS 50μL (25μL / nostril) in the negative control group, and CpG2216 50μg (25μL / nostril) in the positive control group. The experiment was terminated before administration, 3h after administration, 12h after administration, 24h after administration, and 48h after administration, and lung samples were collected to analyze the changes in CXCL-10 mRNA levels by RT-qPCR.
[0367] The experimental results are as follows Fig.32 As shown in the figure, it can be seen that AM1012-05 can effectively stimulate the expression of CXCL-10 in the lungs of mice. And the dosage of 100 μg / mouse showed good immunostimulatory activity. At 24 hours after administration, the mRNA transcription of CXCL-10 reached the highest level. And compared with the CpG 2216 sequence (CpG 2216 is a type A CpG commonly used in the literature), AM1012-05 showed a better immune activation effect.
[0368] Example 37: Observation of respiratory immune indicators after nasal administration of AM1012-05 in mice (different administration frequencies)
[0369] The immune activation ability of AM1012-05 at different dosing rates was evaluated by nasal administration in C57BL6 mice. The animal operation and biological sample detection methods of this experiment were the same as those in Example 36. The test results are shown in Fig.33As shown in the figure (the numbers in brackets on the horizontal axis represent the time of each administration, and day 0 is the end time of the experiment). It can be seen from the figure that AM1012-05 can effectively stimulate the expression of CXCL-10 and IFN-γ in the lungs of mice. And it shows different stimulation effects at different dosing rates. With the increase in the number of dosing times, the mRNA of cytokines has a certain increase. At the same time, the interval between each administration will also significantly affect the immune activation effect. When the interval between each administration is 12h, the stimulation effect is most significant.
[0370] Example 38: Evaluation of in vitro antitumor activity of AM1012-05
[0371] (1) Cultivate and expand MDA-MB-231 and N87 cells, harvest the cells, and resuspend them in 2 mL of complete culture medium;
[0372] (2) Take 10uL of cell suspension, mix it with trypan blue at a ratio of 1:1, and count it using a cell counter. The cell viability is MDA-MB-231: 99.7%; N87: 100%; PBMC: 99.2%, and the cell density is MDA-MB-231: 1.49×10 6 cells / mL; N87:1.12×10 7 cells / mL; human PBMC: 5.17×10 6 cells / mL;
[0373] (3) Resuspend the cells in culture medium and plate 2000 cells / well for MDA-MB-231 cells and 4000 cells / well for N87 cells in 96-well plates;
[0374] (4) After the cells are completely attached, PBMC cells are plated at an effector-target ratio of 10:1;
[0375] (5) The concentrations of AM1012-05 were set to 62.5 nM, 125 nM, 250 nM, 500 nM, 1000 nM, 2000 nM, 4000 nM, and 8000 nM, with six replicate wells for each concentration;
[0376] (6) The cells were cultured for 5 more days and then subjected to CCK8 assay.
[0377] The experimental results are as follows Fig.34 , Fig.35 As shown in the figure, it can be seen that AM1012-05 can effectively stimulate human PBMC to kill tumor cells, and there is a clear dose-dependency. Based on the fact that TLR-9 mainly exists in human pDC and B cells and type A CPG mainly stimulates pDC, this result shows that AM1012-05 enhances the activity of NK cells and CD8 by stimulating pDC. +The ability of T cells to kill tumor cells.
[0378] Example 39: Evaluation of the anti-tumor activity of AM1012-05 combined with CAR-T therapy
[0379] A certain proportion of CAR-T cells and tumor cells were co-cultured, and a specific concentration of AM1012-05 was added. They were incubated together for 3-5 days, and then the free CAR-T cells and tumor cell fragments were removed by changing the medium. A certain amount of CCK8 reagent was added to analyze the activity of the remaining tumor cells, and the tumor cell killing rate of each group was calculated with the untreated and CAR-T groups as controls. The experimental results showed that AM1012-05 can effectively improve the killing of tumor cells by CAR-T cells, and it has a good dose dependence. This shows the synergistic enhancement ability of AM1012-05 on CAR-T therapy.
[0380] Example 40: Evaluation of the anti-allergic rhinitis activity of AM1012-05
[0381] (1) Basal sensitization of BALB / c mice with ovalbumin (OVA): 25 μg OVA and 2 mg Al(OH)3 dissolved in 100 μL saline were intraperitoneally injected into mice on Day 0 / 7 / 14;
[0382] (2) Nasal provocation: Each mouse was given nasal instillation of 20 μL of saline containing 200 μg of OVA on Day 21, Day 22, Day 23, Day 28, Day 29, and Day 30;
[0383] (3) 50 μg of AM1012-05 was administered intranasally 1 h after each challenge;
[0384] (4) After the experiment started, the clinical status of the animals was observed daily until the animals were euthanized, including mental state, activity, diet, drinking water, etc. (After the stimulation, each mouse was observed for 10 minutes, and the number of nose scratching was recorded). At the same time, nasal mucosa, nasal lavage fluid and serum were collected for eosinophil analysis, nasal lavage fluid immune cell analysis and immune index analysis (IFN-γ, IL-4).
[0385] The experimental results are as follows Fig.36 , 37 As shown in the figure, compared with the model group, AM1012-05 administration can effectively reduce the number of sneezes in mice with allergic rhinitis ( Fig.36 A), reduce the number of times you scratch your nose ( Fig.36 B), inhibiting runny nose in mice with allergic rhinitis ( Fig.36 C), reducing the accumulation of eosinophils in the nasal mucosa ( Fig.36D), and can also effectively reduce the IL-4 content in the serum of mice with allergic rhinitis ( Fig.36 E), increasing the expression of IFN-γ ( Fig.36 F in Figure ). Meanwhile, AM1012-05 can reduce neutrophil ( Fig.37 A) and basophils ( Fig.37 These results indicate that AM1012-05 can effectively bias the body's immune response toward the Th1 type, inhibiting the Th2 and Th17 immune responses (a decrease in eosinophils and basophils is a manifestation of a decrease in the Th2 immune response, and a decrease in neutrophils is a manifestation of a decrease in the Th17 immune response), thereby achieving the purpose of treating allergic rhinitis.
[0386] In addition, this experiment verified in mice that IAMA-001 has the function of reducing the number of eosinophils and has the potential to be used in the treatment of eosinophil-related diseases.
[0387] Example 41: Evaluation of the activity of AM1012-05 against respiratory syncytial virus infection
[0388] Experiment 1: Vero-E6 cells were seeded in 24-well plates at a cell density of 2×10 5 cells / mL, cultured for 12-16h until the confluence reached 80%. Then 1000μL of the supernatant of 1-fold and 5-fold dilutions of AM1012-05 co-incubated with human PBMC was added to Vero-E6 cells and incubated for 24h. Then, the cells were infected with respiratory syncytial virus at an MOI of 0.1 for 48h, and then samples were collected to determine the virus replication in each well.
[0389] Experiment 2: Vero-E6 cells were seeded in 24-well plates at a cell density of 2×10 5 cells / mL, and cultured for 12-16 h until the confluence reached 80%. Then AM1012-05 (final concentration: 1 μM), PBMC (2×10 6 Cells / well) were added to a 24-well plate. The cells were then infected with respiratory syncytial virus at an MOI of 0.1 for 48 hours, after which samples were collected to determine the virus replication in each well.
[0390] The results of the two experiments are as follows Fig.38 As shown, the PBMC co-incubation supernatant of AM1012-05 can effectively prevent the proliferation of RSV in cells (Figure A), and AM1012-05 can significantly eliminate RSV in host cells in the presence of PBMC (Figure B).
[0391] Example 42: Evaluation of the anti-atopic dermatitis activity of AM1012-05
[0392] (1) BALB / c were sensitized by injection with 0.5 mL of ovalbumin (OVA) solution (containing 5% aluminum hydroxide) on Day 0, Day 7, and Day 14 of the experiment.
[0393] (2) Preparation for drug administration: The animals were anesthetized and the back hair was shaved and removed to an area of 3*3 cm on Day 20.
[0394] (3) Local stimulation and drug administration: The model group was repeatedly stimulated with a brush to produce slight cracks on the back skin, time: Day 21; PBS group: 50uL PBS was applied to the gauze of a 2*2cm dressing, applied to the back skin and fixed with tape for 24 hours, changed daily, and continued for one week (Day 21-27). After a week's interval, the same treatment was performed for one week (Day 35-41); Other groups: 50μL of 1000μg / mL OVA solution was mixed with the test article or solvent, applied to the gauze of a 2*2cm dressing, applied to the back skin and fixed with tape for 24 hours, changed daily, and continued for one week (Day 21-27). After a week's interval, the same treatment was performed (Day 35-41). Only the test article or solvent was applied for drug administration on Day 28-34.
[0395] (4) On the 35th day of the experiment, the mouse serum was collected for IgE testing.
[0396] The experimental results are as follows Fig.39 As shown in the figure, compared with the OVA model group, AM1012-05 administration can effectively reduce the IgE content in the serum of OVA skin sensitized mice. This result shows that AM1012-05 can effectively inhibit the body's allergic reaction and thus achieve the purpose of treating atopic dermatitis.
[0397] Example 43: Vaccine Immunization in Mice and Testing of Its Potency
[0398] Immunization of mice with vaccines:
[0399] (1) Prepare an appropriate number of Balb / c mice and raise them in isolation and quarantine;
[0400] (2) Mice were grouped according to the experimental requirements, with 5 mice in each group; the negative control was mice injected with S1 protein (S1 protein group);
[0401] (3) Mice were immunized intramuscularly on day 0 (first immunization time), day 14, and day 28, respectively, with a vaccine volume of 50 μL per mouse;
[0402] (4) Daily observation of the clinical status of the animals from the start of the experiment until the animals are euthanized, including mental state, activity level, diet, drinking water, etc.;
[0403] (5) Sample collection: Blood was collected on days 7, 21, 35, 49, 63, and 77. 100–150 μL of whole blood was collected from each mouse each time and centrifuged at 6000 rpm, 4°C, for 10 min to obtain serum.
[0404] (6) Freeze the collected samples at -80°C until titer measurement.
[0405] Detection of mouse immune titer:
[0406] (1) Protein coating: The coating concentration of SARS-CoV-2S1 protein is 2 μg / ml. Dilute the protein concentration. Add the diluted sample to a 96-well ELISA plate, add 100 μL to each well, seal the plate with a sealing film, and place in a 4°C refrigerator overnight;
[0407] (2) Washing: Take out the 96-well plate coated overnight, discard the liquid in the wells, wash three times with PBS, 300 μL / well, and pat dry;
[0408] (3) Blocking: Add 300 μL of 2% BSA blocking buffer to each well, seal the plate with a sealing film, and incubate at 37°C for 1 h;
[0409] (4) Washing: After blocking, discard the liquid in the wells, wash three times with PBST, 300 μL / well, and pat dry;
[0410] (5) Primary antibody incubation: Add 100 μL of diluted sample (serum) to each well, seal the plate with a sealing film, and incubate at 37°C for 1 h;
[0411] (6) Washing: After incubation, discard the liquid in the wells, wash three times with PBST, 300 μL / well, and pat dry;
[0412] (7) Secondary antibody incubation: Add 100 μL of diluted secondary antibody to each well, seal the plate with sealing film, and incubate at 37°C for 1 h;
[0413] (8) Washing: After incubation, discard the liquid in the wells, wash with PBST 5 times, 300 μL / well, and pat dry;
[0414] (9) Color development: Add 100 μL TMB color development solution to each well and develop at 37°C;
[0415] (10) Stop: Add 50 μL of ELISA stop solution and gently tap the edge of the ELISA plate to mix;
[0416] (11) Reading the plate: Place the ELISA plate in an ELISA reader and read the plate at a detection wavelength of 450 nm and a reference wavelength of 570 nm.
[0417] Analysis and discussion of immune results:
[0418] In mice, the total IgG antibody titer reflects the overall immune level of the vaccine, IgG1 reflects the humoral immunity level, and IgG2a reflects the cellular immunity level. Most traditional adjuvants have good humoral immunity activation ability (mouse IgG1), but weak cellular immunity level (mouse IgG2a). Therefore, the development of vaccine adjuvants that can effectively stimulate the production of IgG2a antibodies has been a key research direction of the adjuvant industry in recent years. In addition, Dynavax's CpG 1018 is currently the only CpG adjuvant in the world that has been approved for human vaccine production (CpG 1018 is used as an independent adjuvant for hepatitis B vaccine production). In this experiment, the S1 protein of the new coronavirus was used as a model antigen, and CpG1018 was used as a CpG positive adjuvant control to evaluate the adjuvant application of AM1012-05 of the vaccine prepared in Example 32 and Example 33. The results of the IgG, IgG1 and IgG2a antibody titer tests after mice were immunized with the AM1012-05 related vaccine are shown in the figure. Fig.40 , Fig.41 , Fig.42 shown.
[0419] from Fig.40 It can be seen that in the early stage of immunization, the IgG immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate was significantly better than that of the single aluminum phosphate adjuvant ( Fig.40 The IgG immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate was significantly better than that of the marketed CpG adjuvant 1018 ( Fig.40 The IgG immune titer of the adjuvant system composed of AM1012-05 and aluminum hydroxide is also better than that of the marketed CpG adjuvant 1018 ( Fig.40 The IgG immune titer of AM1012-05 as an independent adjuvant is comparable to that of the marketed CpG adjuvant 1018 ( Fig.40 (Medium AE).
[0420] from Fig.41 It can be seen that in the early stage of immunization, the IgG1 immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate or aluminum hydroxide was significantly better than that of the marketed CpG adjuvant 1018 ( Fig.41 In the middle and late stages of immunization, the IgG1 immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate or aluminum hydroxide was also significantly better than that of the marketed CpG adjuvant 1018 ( Fig.41 The IgG1 immune titer of AM1012-05 as an independent adjuvant is comparable to that of the marketed CpG adjuvant 1018 ( Fig.41 (Medium AE).
[0421] from Fig.42 It can be seen that the IgG2a immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate is significantly better than that of the marketed CpG adjuvant 1018 ( Fig.42 The IgG2a immune titer of the adjuvant system composed of AM1012-05 and aluminum phosphate was also significantly better than that of aluminum hydroxide and aluminum phosphate adjuvants ( Fig.42 In the early and middle stages of immunization, the IgG2a immune titer of AM1012-05 as an independent adjuvant was also significantly better than that of the marketed CpG adjuvant 1018 ( Fig.42 In the early stage of immunization, the IgG2a immune titer of the adjuvant system composed of AM1012-05 and aluminum hydroxide was significantly better than that of the listed CpG adjuvant 1018, aluminum hydroxide adjuvant and aluminum phosphate adjuvant ( Fig.42 (middle AB).
[0422] From the above evaluation results of the immune potency of vaccines using AM1012-05 as an independent adjuvant or as an adjuvant system composed of an aluminum adjuvant (aluminum hydroxide or aluminum phosphate), it can be seen that AM1012-05 can significantly improve the humoral immunity and cellular immunity levels of the vaccine, especially the adjuvant system composed of AM1012-05 and aluminum phosphate can significantly improve the cellular immunity level of the vaccine, and its immune effect is much higher than the commercially available CpG adjuvant 1018 and aluminum adjuvant (aluminum hydroxide or aluminum phosphate). In addition, in terms of early protection of vaccines, the adjuvant system composed of AM1012-05 and aluminum adjuvant (aluminum hydroxide or aluminum phosphate) is far superior to the commercially available CpG adjuvant 1018 and aluminum adjuvant (aluminum hydroxide or aluminum phosphate).
[0423] Therefore, AM1012-05 as an independent adjuvant or an adjuvant system composed of an aluminum adjuvant (aluminum hydroxide or aluminum phosphate) has very significant advantages over existing aluminum adjuvants (aluminum hydroxide or aluminum phosphate) and CpG adjuvants in terms of earlier onset of immune protection effect and improved immune protection effect. It is a very advantageous vaccine adjuvant or adjuvant system.
[0424] The present application is described in detail above in conjunction with specific implementation methods and exemplary examples, but these descriptions cannot be understood as limiting the present application. Those skilled in the art understand that, without departing from the spirit and scope of the present application, a variety of equivalent replacements, modifications or improvements can be made to the technical solution of the present application and its implementation methods, all of which fall within the scope of the present application. The scope of protection of the present application shall be subject to the attached claims.
Claims
1. A CpG oligodeoxynucleotide with the ability to regulate immunity. It is characterized in that The CpG oligodeoxynucleotide has a structure of 5'-(G) n -Core Sequence-(N) q -(G) m- 3', the core sequence is a palindromic sequence, the N is any one of the three bases of adenine deoxyribonucleotide A, thymine deoxyribonucleotide T, and cytosine deoxyribonucleotide C; the G is guanine deoxyribonucleotide; the q, n, and m are all integers, the n value range is 2 to 11, the q value range is 0 to 10, and the m value range is 2 to 11.
2. The CpG oligodeoxynucleotide having the ability to regulate immunity according to claim 1, Features: The value range of n is 3-4, and the value range of q is 1-5.
3. The CpG oligodeoxynucleotide having the ability to regulate immunity according to claim 1, Features: The core sequence is at least one of CGCGACGCGTCGCG, ACGATCGAGATCGT, AGGATCGATCC T, TTCGATCGATCGAA, CGATCGATCG, GACGATCGTC, and TGCATCGATGCA; When the core sequence is CGCGACGCGTCGCG, the value range of q is 0 to 10, the value range of n is 0 to 3, and the value range of m is 2 to 11; Or, when the core sequence is ACGATCGAGATCGT, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11; Or, when the core sequence is AGGATCGATCCT, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11; Or, when the core sequence is TTCGATCGATCGAA, the value range of q is 0 to 10, the value range of n is 2 to 11, and the value range of m is 2 to 11; Or, when the core sequence is CGATCGATCG, the value range of q is 0 to 10, the value range of n is 1 to 11, and the value range of m is 2 to 11; Or, when the core sequence is GACGATCGTC, q is 0, n is in the range of 0 to 3, and m is in the range of 2 to 11; or q is in the range of 1 to 10, n is in the range of 2 to 11, and m is in the range of 2 to 11; Or, when the core sequence is TGCATCGATGCA, q is 0, n is 1, 3, 4 or 5, and m is in the range of 2 to 11; or q is in the range of 1 to 10, n is in the range of 2 to 11, and m is in the range of 2 to 11.
4. The CpG oligodeoxynucleotide having the ability to regulate immunity according to claim 1, Features: It comprises at least one of the deoxynucleotide sequences shown in SEQ ID NO.1 to SEQ ID NO.
82.
5. The CpG oligodeoxynucleotide having the ability to regulate immunity according to any one of claims 1 to 4, Features: The CpG oligodeoxynucleotide itself may contain at least one of thio modification, fluoro modification, methoxy modification, locked nucleic acid modification, and nanoparticle modification.
6. The CpG oligodeoxynucleotide having the ability to regulate immunity according to claim 5, Features: The thiolation modification site is on the polyguanylate at the 5' end and / or the 3' end.
7. The CpG oligodeoxynucleotide having the ability to regulate immunity according to claim 5, Features: The nanoparticles used in the nanoparticle modification include at least one of PLGA, chitosan, lipid nanoparticles and liposomes.
8. A CpG oligodeoxynucleotide solution preparation, Features: The invention comprises the CpG oligodeoxynucleotide according to any one of claims 1 to 7 and excipients, wherein the excipients comprise at least one of pH buffer pair, glycine, trehalose, mannitol, sucrose, arginine, lysine, histidine, glycerol, propylene glycol, Pluronic F127, Pluronic F68, Tween 20, Tween 80, benzalkonium chloride, disodium edetate, sodium citrate, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methyl beta-cyclodextrin and polyethylene glycol.
9. A CpG oligodeoxynucleotide solution preparation according to claim 8, Features: The metal ions of the CpG oligodeoxynucleotide preparation include sodium, potassium, magnesium, calcium, zinc and iron, and the total concentration ranges from 0.1 to 90 mM.
10. A CpG oligodeoxynucleotide solution preparation according to claim 8, Features: The pH value of the CpG oligodeoxynucleotide preparation is between 7-9.
11. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for regulating respiratory immune response.
12. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for preventing and treating respiratory diseases, It is characterized in that The respiratory tract disease includes at least one of respiratory viral infectious diseases, respiratory bacterial infectious diseases, respiratory fungal infectious diseases, respiratory parasitic infectious diseases, and respiratory allergic diseases.
13. Use of the CpG oligodeoxynucleotide according to claim 12 in the preparation of a drug for preventing and treating respiratory diseases, It is characterized in that The respiratory virus includes at least one of COVID-19 virus, influenza virus, RSV virus, and SARS-Cov.
14. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for preventing and treating a disease not caused by respiratory infection, It is characterized in that The non-respiratory tract infection disease includes at least one of HIV virus infection, HBV virus infection, and HCV virus infection.
15. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for regulating the proliferation function of immune cells or a drug for regulating the release of cytokines from immune cells.
16. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of an immune adjuvant.
17. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for preventing and treating viral infection.
18. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for treating tumors, Features: In the drug, CpG oligodeoxynucleotide is the only anti-tumor drug component.
19. An antitumor composition, It is characterized in that The composition comprises the CpG oligodeoxynucleotide according to any one of claims 1 to 6 and an anti-tumor drug, wherein the anti-tumor drug includes but is not limited to a PD-1 anti-tumor drug, a PDL-1 anti-tumor drug and an anti-tumor cell therapy, and the CpG oligodeoxynucleotide in the composition serves as a component with anti-tumor efficacy or an immune adjuvant.
20. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of vaccines for human or animal use.
21. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in treating central nervous system diseases, It is characterized in that The central nervous system diseases include but are not limited to Alzheimer's disease.
22. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for preventing and treating secondary infection after trauma.
23. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a drug for promoting wound healing.
24. Use of the CpG oligodeoxynucleotide according to any one of claims 1 to 7 in the preparation of a medicament for treating allergic rhinitis and / or atopic dermatitis and / or asthma and / or chronic obstructive pulmonary disease and / or eosinophil-related diseases.
25. A drug prepared by using the CpG oligodeoxynucleotide according to any one of claims 1 to 7, It is characterized in that The dosage form of the medicine is injection, tablet, lyophilized agent, inhalation, nasal drops, nasal spray, rectal suppository, eye drops, ointment, lotion and gel.
26. A CpG oligodeoxynucleotide preparation for external use, Features: The invention comprises the CpG oligodeoxynucleotide as claimed in any one of claims 1 to 7 and excipients, wherein the excipients comprise glyceryl behenate, liquid paraffin, vaseline, medium chain triglycerides, cocoyl caprylate, glyceryl mono- and distearate, hydroxypropyl methylcellulose, carbomer, xanthan gum, sodium carboxymethyl cellulose, poloxamer 407, polyethylene glycol cetearyl alcohol ether, poloxamer 188, oleoyl polyoxyethylene glyceride, polyethylene glycol-7 stearate, caprylic capric macrogol glyceride, sodium lauryl sulfate, propylene glycol monofatty acid ester, polyglyceryl oleate, propylene glycol laurate, propylene glycol, isopropyl myristate, and polyglyceryl oleate.
27. A CpG oligodeoxynucleotide adjuvant and a preparation combined with other types of adjuvants for use in vaccines for human or animal use, Features: The method comprises the CpG oligodeoxynucleotide according to any one of claims 1 to 7, itself, or a combination thereof with an aluminum hydroxide adjuvant or an aluminum phosphate adjuvant.
Citation Information
Patent Citations
Immunostimulatory oligonucleotide and pharmaceutical application thereof
CN101460620A
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CN110770345A
Multiple CpG oligodeoxynucleotides with immunostimulatory activity and application thereof
CN114807153A
CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application
CN1810970A
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US20110060035A1
Cited By
Adjuvanted influenza vaccine and use thereof
WO2026157971A1
